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ABSTRACT 
 
Alcohol Regulates Genes that are Associated with Response to Endocrine Therapy and 
Attenuates the Actions of Tamoxifen in Breast Cancer Cells 
Pancreatic ductal adenocarcinoma (PDAC) is difficult to detect early and is often resistant to 
standard chemotherapeutic options, contributing to extremely poor disease outcomes. Members 
of the nuclear receptor superfamily carry out essential biological functions such as hormone 
signaling and are successfully targeted in the treatment of endocrine-related malignancies. Liver 
X receptors (LXRs) are nuclear receptors that regulate cholesterol homeostasis, lipid metabolism, 
and inflammation. Intriguingly, LXR agonists exhibit antiproliferative activity in diverse types of 
cancer cells. In this study, LXR agonist treatments disrupted proliferation, cell-cycle progression, 
and colony-formation of PDAC cells. At the molecular level, treatments downregulated expression 
of proteins involved in cell cycle progression and growth factor signaling. Microarray experiments 
further revealed changes in expression profiles of multiple gene networks involved in biological 
processes and pathways essential for cell growth and proliferation following LXR activation. 
These results establish the antiproliferative effects of LXR agonists and potential mechanisms of 
action in PDAC cells and provide evidence for their potential application in the prevention and 
treatment of PDAC.  
 
The Antiproliferative Properties and Mechanisms of LXR Ligands on Pancreatic Ductal 
Adenocarcinoma Cells  
Hereditary, hormonal, and behavioral factors contribute to the development of breast cancer. One 
modifiable behavioral factor, alcohol consumption, is linked to breast cancer risk. In this study we 
characterized molecular mechanisms of action of alcohol in estrogen receptor (ER)-positive 
breast cancer cells. Treatments with alcohol promoted cell proliferation, increased growth factor 
signaling, and up-regulated the transcription of the ER target gene GREB1. Microarray analysis 
following alcohol treatment identified a large number of alcohol-responsive genes, which were 
strongly associated with clinical outcomes in patients who received endocrine therapy. 
vii 
Correspondingly, alcohol treatment attenuated the anti-proliferative effects of the endocrine 
therapeutic drug tamoxifen in ER-positive breast cancer cells. To determine the contribution and 
functions of responsive genes, their differential expression in tumors were assessed between 
outcome groups. The proto-oncogene BRAF was identified as a novel alcohol- and estrogen-
induced gene that showed higher expression in patients with poor outcomes. Knock-down of 
BRAF, moreover, prevented the proliferation of breast cancer cells. These findings not only 
highlight the mechanistic basis of the effects of alcohol on breast cancer cells and increased risks 
for disease incidents and recurrence, but may facilitate the discovery and characterization of 
novel oncogenic pathways and markers in breast cancer research and therapeutics. 
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1. Introduction 
1.1 The Nuclear Receptor Superfamily  
1.1.1 Nuclear Receptor Ligands and Mechanisms 
 
Nuclear receptors (NRs) encompass a large family of transcription factors that sense 
biochemical changes within metazoans and alter physiological responses to changing internal 
and external conditions[1,2]. Members of the nuclear receptor superfamily evolved from a single 
ancestral NR to the current 48 found in humans [1,3,4]. These proteins regulate metabolic, 
developmental, and homeostatic cellular processes in response to dynamic levels of lipophilic 
signaling molecules (ligands), which can act as activators, repressors, or modulators by binding 
and altering NR structure and function [3]. Structurally, NR signaling ligands are thyroid, retinoid, 
steroid derivatives, or metabolic biproducts, and target specific domains within their cognate NRs. 
A nuclear receptor and its ligands orchestrate their effects on physiology largely by altering gene 
transcription in the nucleus, a process that drives pathology under a variety of conditions when 
improperly regulated. The prototypical nuclear receptor contains a ligand binding, DNA binding, 
and transactivating domain [3]. The DNA-binding domain contains two zinc fingers that bind to 
specific genomic sequences known as hormone response elements (HREs) [2]. Furthermore, 
ligand complexing with the nuclear receptor initiates structural changes within the ligand binding 
domain, exposing discrete sites to allow for the docking of coactivators, proteins that direct 
chromatin remodeling proximal to a target gene promoter [2,5,6].  As the precise cellular 
mechanisms vary between nuclear receptors, a more complete mechanism of nuclear receptor 
activity will be detailed hereafter (Sections 1.2.1 and 1.3.2).   
 
1.1.2 Evolutionary Relationships within the Nuclear Receptor Superfamily 
 
There is a significant amount of structural and functional variety between nuclear 
receptors. The Nuclear Receptors Nomenclature Committee developed a widely used standard 
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for naming nuclear receptors [4]. Each NR was categorized according to its evolutionary history, 
function, and general mechanism. There are currently 7 nuclear receptor subfamilies, and this 
dissertation will focus on two specific members (LXR and ER) found within two separate families 
(the first and third subfamilies), representing different general mechanisms and therefore different 
scientific considerations. Family one contains the thyroid hormone receptors (TRα/TRβ), retinoic 
acid receptors (RARα, RARβ, RARγ), peroxisome proliferator-activated receptors (PPARα, 
PPARβ, PPARγ), the liver-X receptors (LXRα and LXRβ), the vitamin D receptor (VDR), and the 
farnesoid-X receptor (FXR) among others. The third family contains the estrogen receptors (ERα, 
ERβ), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone receptor (PR), 
and androgen receptor (AR). All the receptors mentioned within these two categories are known 
to bind a ligand [2-4]. Interestingly, there are nuclear receptors for which we have yet to identify a 
ligand, and those that could not possibly bind a ligand in the traditional sense as they lack an 
open ligand-binding pocket (such as Nurr1) [7]. These receptors are referred to as “orphan” 
nuclear receptors. There are also NRs that lack a DNA-binding domain (SHP for instance), and 
are not technically “transcription factors” but are still classified as nuclear receptors due to 
sequence homology with the nuclear receptor superfamily [1,4]. These receptors are very 
important for the activity of other NRs (such as LXR and FXR) and are not nuclear receptor 
pseudogenes.  
 
1.1.3 RXR Dimerization Partner Receptors 
 
 
Members of the large subfamily group I of nuclear receptors (TRα, TRβ, et al.) bind to 
DNA as heterodimers with the retinoid X receptors (RXRα, RXRβ, and RXRγ) [1,2]. The RXRs 
are activated by 9-cis retinoic acid ligands. Therefore, two activating ligands are required for 
optimal transactivation, conferring bimodal and combinatorial controls of nuclear receptor 
function, in contrast to group 3 nuclear receptors (ERα, GR), which generally bind to DNA as 
homodimers in response to a singular activating ligand [2,8]. The members of subfamily group I 
are thought to compete with one another for available ligand bound RXR, which raises questions 
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about the binding affinities for different isoforms of RXR and partner nuclear receptors, and how 
tissue specific expression of RXR isoforms and competition may reconfigure tissue specific 
responses to lipid ligands (PPAR), bile acid (FXR), and oxysterols (LXR) [4,9,10]. Regardless, 
RXR can form heterodimers to orient the nuclear receptor DNA binding domain to recognize 
palindromic, direct, or inverted repeat HREs [1,2]. The RXR and nuclear receptor dimerize along 
a hydrophobic repeat region lining the LBD, and is supported by a dimerization surface that forms 
upon DNA binding [2,11]. A set of RXR dimerization partners, the LXRs (LXRα/LXRβ), have been 
shown to regulate a wide variety of processes including reverse cholesterol transport, bile acid 
synthesis, lipid biosynthesis, as well as the proper secretion of pancreatic digestive juices into the 
intestine [12-15]. The LXRs are also involved in a variety of disease states.  These receptors 
have been shown to regulate proliferation in a variety of cancers from different tissues upon 
activation with synthetic ligands. Critical processes in normal LXR function will be detailed, as 
well as its links to cancer cell proliferation, in the following sections.  
 
1.2 Introduction: The LXRs in Health and Human Disease 
1.2.1 Ligands and Transcriptional Regulatory Mechanisms of the LXRs 
 
 
Two LXRs, LXRα (NR1H3) and LXRβ (NR1H2), were first identified as orphan NRs (or 
NRs lacking an activating ligand), and have been shown to heterodimerize with 9-cis retinoic acid 
receptors (RXRs) [16,17]. The LXRs have alternative tissue-specific expression profiles. LXRβ 
appears to be expressed ubiquitously, while LXRα expression is confined to the liver, intestine, 
lung, macrophages, kidney, and the adrenal glands [18]. Several endogenous agonists of LXR 
have recently been identified, such as 24-hydroxycholesterol, 20(S)-hydroxycholesterol, 22(R)-
hydroxycholesterol, and 4β-hydroxycholesterol [19]. After their initial cloning and basic 
characterization, two synthetic agonists, GW 3965 and T 0901317, were developed [20,21]. 
These ligands bind to and activate both LXRα and LXRβ. An LXRβ-specific ligand has also been 
characterize, 5,6-24(S),25-diepoxycholesterol, as well as several LXR antagonists, such as 
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arachadonic acid and riccardin [22-25]. The identification of LXR ligands has facilitated the study 
of transcriptional regulatory mechanisms of the LXRs.  
Generally, the NRs found in the NR superfamily group 1 (such as LXR), are thought to 
immediately translocate to the nucleus, where they bind to hormone response elements 
throughout the genome. In the classical mechanisms of NRs in subgroup 1, NRs recruit 
corepressors (i.e. SMRT) in the absence of ligand [1,2]. Corepressor complexes contain histone 
deacetaylases (HDACs), which remove transcription stimulatory signals on histone tails proximal 
to gene promoters. In the presence of a stimulating ligand, group 1 NRs recruit transcriptional 
coactivators instead of corepressors, leading to gene activation. However, chromatin 
immunoprecipitation experiments have shown that the LXRs bind to DNA in a ligand-dependent 
manner, much like estrogen receptor or other NR members of subgroup 3 [26]. Chromatin 
immunoprecipitation also demonstrate that LXR binds to many elements throughout the genome 
without an identifiable LXRE, suggesting that the canonical binding site for LXR is variable, or that 
LXR tethers to other transcription factors bound to DNA. LXRα and LXRβ bind preferentially to 
AGGTCAnnnnAGGTCA (LXRE), a direct repeat separated by four non-contacted bases. More 
detailed mechanisms of LXR and its regulated genes have led to a better understanding of the 
roles of LXR in physiology. Generally, the LXRs are known to regulate organism wide cholesterol 
levels by regulating the elimination of (1) cholesterol from the body, (2) the amount of cholesterol 
absorbed from ingested food, and (3) the amount of cholesterol synthesized in the liver [18]. 
Furthermore, due to their roles in regulating the amounts of serum triglycerides, lipoprotein 
particle assembly and regulation will be explored in Section 1.1.2 first. It is through these 
regulatory pathways that LXR modulation may result in better treatments for atherosclerosis, 
diabetes, or cancer.  
 
1.2.2 The Role of LXR Ligands in Cholesterol Efflux 
 
 The LXRs promote bile acid synthesis of endocytosed LDL-associated cholesterols in the 
liver [18]. It was suggested that the LXRs regulated cholesterol metabolism in the liver due to (1) 
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the discovery of cholesterol metabolites as endogenous ligands of the LXRs, and (2) the 
identification of cholesterol ester accumulation in the liver of LXRα-/- mice [15,27]. These LXRα-/- 
mice were unable to convert effluxed cholesterol esters from peripheral tissues into bile acids. 
This accumulation results in murine hepatomegaly with extensive macrophage infiltration, which 
is suggestive of hepatitis [15]. Interestingly, LXRβ-/- mice do not accumulate cholesterol in the 
liver, but tend to have smaller adipocytes, and have impaired glucose-dependent insulin secretion 
[28,29]. Activation of the LXRs with synthetic ligands has been shown to both increase serum 
HDL levels, the antiatherosclerotic lipoprotein particle, and decrease net cholesterol levels in the 
peripheral tissues [30]. This effect depends on LXR-mediated induction of ABCA1 and ABCG1, 
leading to the export of fatty compounds to HDL throughout the body [31]. Furthermore, these 
basic mechanisms appear to occur in most, if not all, the tissues throughout the body. 
These effects are due to diverse tissue specific effects of the LXRs, which have been well 
characterized in the liver, macrophages, and intestine. [32]. It was demonstrated that ABCA1 was 
induced in a mouse model of intestinal LXRα with constitutive activity (iVP16LXRα). ABCG5 and 
ABCG8 were also upregulated in these mice, which serves to limit the amount of dietary 
cholesterol absorbed. Constitutive LXRα mice were able to efflux cholesterol directly to HDL from 
the intestinal enterocytes. Expression of NPC1L1, which regulates the absorption of dietary 
sterols, was suppressed by constitutive LXRα activity. Overall, the absorption of dietary 
cholesterol was reduced in these mice, leading to increased hepatic cholesterol synthesis [33]. 
LXRα activation in the intestine is protective against atherosclerosis in LDLR-deficient mice, 
which suggests that the intestine is an important regulator in the pathogenic accumulation of fats 
in the arteries.  
LXRs play an important role in regulating the use of these absorbed nutrients after uptake 
in the liver. Treatment of mice with LXR ligands has been shown to increase de novo lipogenesis 
in the liver [34,35]. This leads to increased increased lipid accumulation in the liver, as well as 
increased serum triglyceride levels (resulting in increased VLDL levels), which are the results of 
LXR-mediated upregulation of SREBF1, or sterol regulatory element-binding factor 1 [36]. 
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SREBF1 is a basic helix-loop-helix transcription factor that regulates the production of fatty acids 
for export from the liver, and contains an LXRE in the gene promoter. SREBF1 upregulates fatty 
acid synthase, steroyl-CoA desaturase 1, and acyl-CoA carboxylase, key enzymes that mediate 
de novo lipogenesis [37]. Acyl-CoA carboxylase synthesizes malonyl-CoA from acetyl-CoA, 
byproducts of glycolysis. Fatty acid synthase catalyzes the formation of palmitate from malonyl-
CoA and acetyl-CoA precursors. Steroyl-CoA desaturase introduces a double bond into the newly 
formed fatty acid, resulting in the generation of monounsaturated fats. Furthermore modifications 
result in the conversion of these fatty acids into phospholipids and triglycerides for direct use or 
export. This is thought to be the principle mechanism whereby the LXRs upregulate fatty acid 
synthesis.  
LXR agonists have also been shown to reduce glucose tolerance in rodent models of 
diabetes [38,39]. First, PGC-1 levels in the liver are suppressed, which is an activator of 
gluconeogenic genes glucose-6-phosphatase, and phosphenolpyruvate carboxykinase (PEPCK). 
These downstream targets of PGC-1 are also repressed [38]. PEPCK generates a 
phosphoenolpyruvate molecule from oxaloacetate, and is the rate-limiting enzyme in 
gluconeogenesis [40]. Glucose-6-phosphotase hydrolyzes glucose-6-phosphate, yielding a 
phosphate group and a glucose molecule, and is the final step in gluconeogenesis [41]. 
Conversely, insulin sensitive glucose transporter GLUT4 is upregulated in adipocytes. Together, 
these data suggest that the LXRs activate transcription of genes involved in limited 
gluconeogenesis in the liver, and increase glucose uptake in peripheral cells through GLUT4 
activation [38]. Enhanced LXRβ signaling in MIN6 pancreatic islet cells increased insulin 
secretion in the presence of glucose, as well as lipogenic genes fatty acid synthase and acetyl-
CoA carboxylase [29,42].  This effect was attenuated in LXRβ-/- mice. LXRβ-/- mice tend to 
accumulate lipids in the islets themselves, and lose glucose dependent insulin secretion. To be 
clear, the LXRβ-/- mice are glucose intolerant, but not insulin resistant [29]. These data link LXRs 
and their ligands not only to lipid synthetic mechanisms in target cells, but also to glucose uptake 
and homeostasis in the endocrine pancreas.  
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Cholesterols that accumulate in the macrophages have been shown to function as 
endogenous ligands for LXR [18]. This results in the upregulation of ABCA1 and ABCG1 as a 
means to efflux cholesterol that has accumulated in the arteries to HDL particles. Both ABCA1 
and ABCG1 contain bona fide LXREs, which mediate their induction upon ligand stimulation [43] 
[44]. A summary of the mechanisms in this section is depicted in Figure 1.1. In addition to their 
effects on cholesterol, blood glucose, and fatty acid synthetic gene networks, the LXRs are also 
known to modulate inflammatory signaling in macrophages and other tissues. A better 
understanding of these roles is of particular importance to atherosclerotic macrophages as well 
as general autoimmune diseases and immunogenic cancers. LXR ligands are able to repress 
inflammatory mediators, such as COX2, IL-6, MCP-1, and MMP9; in response to challenge with 
LPS (lipopolysaccharide) and TNF-α [45]. This effect is attenuated when both LXRα and LXRβ 
are knocked out, as there appears to be redundant compensation with these anti-inflammatory 
mechanisms when either is knocked out in isolation [45]. Interestingly, TLR3 and TLR4 activation 
result in the inhibition of LXRs through activated interferon-regulatory factor 3 [46]. LXR ligands 
have also been shown to decrease the severity of experimental autoimmune encepephalomyelitis 
[47]. In these treated mice, reduced expression of MHC II in the microglia, as well as reduced 
overall inflammation in the CNS.  LXRαβ-/- mice experience more aggressive inflammatory 
responses when challenged with LPS treatment. Furthermore, it has been shown that LXR 
agonists improve symptoms in a model of contact dermatitis similar to steroid based anti-
inflammatories such as dexamethasone [8,48]. Inflammatory mediators in macrophages do not 
appear to contain LXREs, which suggests independent tethering of LXR to other transcription 
factors. The LXRs likely transrepress selected NFκB response elements in a manner similar to 
other nuclear receptors, such as GR, ER, and VDR [46,49]. Taken together, these results 
demonstrate the centrality of the LXRs to body-wide cholesterol localization, bile acid synthesis, 
lipogenesis, response of the endocrine pancreas to blood glucose levels, and inflammatory 
signaling.   
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Due to the discovery that the LXRs target (an unintended) set of lipogenic genes, LXR 
agonists are thus far insufficient for widespread use in humans. However, because of their known 
roles in reverse cholesterol transport and inflammation, the LXRs still represent potential drug 
targets under the condition that more mechanism specific therapies are developed. There are 
examples of compounds that circumvent undesirable effects of particular NR ligands such as 
dissociated ligands that target specific transcriptional submechanisms of an NR, partial agonists, 
and modulators with mixed agonist/antagonist properties depending on the tissue. Ligands of 
these different varieties have been developed for estrogen receptor, glucocorticoid receptor, and 
androgen receptor. In the case of LXR, there is interest in developing a ligand that activates 
reverse cholesterol transport, but does not promote lipogenesis in the liver. Where LXRα-/- mice 
accumulate cholesterol in the liver hepatocytes, LXRβ-/- mice do not [15,28]. Therefore, there is 
interest in generating LXRβ-specific ligands, which may circumvent the lipogenic effects of LXRα. 
Despite a highly conserved ligand binding domain that is shared between LXRα and LXRβ, an 
LXRβ preferring ligand (179 nm for LXRα and 24 nm for LXRβ) has been developed (LXR 623) 
that promotes reverse cholesterol transport but does not induce lipogenesis in the liver [50]. 
These drugs proceeded to clinical trials but were halted after patients experienced central 
nervous system side effects, which is further evidence of extensive roles for LXR beyond the 
blood-brain barrier. Due to their widespread expression and their diverse effects on inflammatory 
and metabolic pathways, it makes targeting intended mechanisms more difficult. As these ligands 
have thus far have failed as treatments for atherosclerosis, diseases that have a much higher 
threshold for allowable adverse effects represent an opportunity for the further advancement of 
these ligands. For instance, these ligands are being explored as anti-cancer agents in a variety of 
different tissues. Many of these cancers have limited treatment options with a dim prognosis, 
such as cancer of the ovary, pancreas, and breast.  
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1.2.3 The Anti-proliferative Effects of Liver X Receptor Ligands 
 
Nuclear receptors are currently the target of many compounds as they are highly 
druggable and can be modulated with compounds that target mechanisms of nuclear receptor 
function. Several nuclear receptors are targeted in the treatment of cancers of breast and 
prostate, such as ARs and ERs. ERs are targeted directly by small molecule anti-estrogens and 
selective estrogen receptor modulators (SERMs; tamoxifen; raloxifene) or indirectly by aromatase 
inhibitors (letrozole, exemestane, anastrozole) as a means to block endogenous estrogen 
production [51]. Because NRs have a hydrophobic pocket within the ligand-binding domain, they 
are able to bind a diverse set of compounds, natural or synthetic, that have unique effects on NR 
activity, physiology, and disease states [2]. This is in contrast to other non-NR transcription 
factors with inaccessible globular protein structures that significantly limit the development of 
small-molecule inhibitors.  
Based on the well-characterized effects of ER on breast/ovarian cancer and AR on 
prostate cancer, it is likely that other NRs and their ligands regulate cancer progression in tissues 
throughout the body. Interestingly, it has been shown that epoxycholesterols accumulate in 
malignant prostate cancers [52,53]. Furthermore, SREBF1 and SREBF2, are upregulated in 
these prostate cancers. The presence of endogenous LXR ligands and activated SREBF1 
suggested a potential role for the LXRs in prostate cancer development and progression. To test 
this hypothesis, mouse models of prostate cancer were treated with T0901317, which resulted in 
decreased tumor formation [54]. Overexpression of LXRα in these cells prior to injection resulted 
in increased sensitivity to the LXR ligand. Due to these observations in prostate cancer, the 
effects and mechanisms of the LXRs are being evaluated as potential therapeutic targets in 
diverse cancers.  
After the initial characterization of the antiproliferative effects of LXR in prostate cancer, 
many studies have shown the effects of LXR ligands on cell cycle signaling pathways in diverse 
cancers. For instance, treatment of prostate cancer cells with LXR ligands leads to increased p27 
protein levels, a cyclin-dependent kinase inhibitor [54]. SKP, an oncogene found in a large E3 
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ubiqutin ligase complex, was decreased in LNCaP cells after treatment with LXR ligands. 
Furthermore, SKP2 has been shown to target p27 for protesomal degradation, which is indicative 
of a potential antiproliferative mechanism. The effects on the protein levels in prostate cancer cell 
lines appear to be independent of a direct transcriptional mechanism, as the mRNA for these 
genes are unaffected by ligand treatment. It has further been shown that SKP2 transcript and 
protein levels are decreased in breast cancer cell lines, but p21 and p27 remain unaffected, 
suggesting alternative mechanisms of regulated by the LXRs between prostate and breast 
cancers [55].  LXR Ligand treatment and microarray analysis of breast cancer cell lines revealed 
an enrichment of repressed genes regulated by E2F2, which is also downregulated by LXR ligand 
treatment [56]. E2F family members are transcription factors integrally linked to cell cycle 
regulation. LXR agonists are also antiproliferative in breast cancer cell lines by disrupting both 
ER-dependent proliferation and cell cycle machinery [55,56]. Furthermore, LXR ligands have 
been shown to induce apoptosis in prostate, ovarian, breast cancers; and B cell leukemia 
[54,57,58]. These studies demonstrate a consistent effect of LXR ligands on cancer cell cycle and 
apoptosis pathways from a variety of cancers and tissues.  
The effects of LXR ligands on cancer cell growth may be due to their well-documented 
effects on metabolism. Fatty compound transporter ABCA1 has been shown to be downregulated 
in malignant prostate cancer cells [59]. Knockdown of this transporter has been shown to 
increase prostate cancer cell proliferation. Interestingly, ABCA1 is an induced target of the LXRs, 
and may provide a mechanistic link between LXR ligands and the observed effects on cell 
proliferation. ABCG1, another cholesterol transporter and induced target of LXR, has been shown 
to increase AKT1 signaling, resulting in apoptosis in prostate cancer cell lines [60]. Activated 
targets of LXR, ABCA1 and ABCG1, are known to efflux excess cholesterol to HDL particles. As 
part of this mechanism, LXR ligands have been shown to downregulate LDLR expression, which 
accepts lipoprotein particles consisting primarily of cholesterol used in downstream mechanisms 
[61]. Both these mechanisms exist to limit cholesterol uptake. Suppression of LDLR expression 
through LXR treatment resulted in apoptosis in glioblastoma cells, and represents another 
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potential mechanism for the antiproliferative effects of the LXRs. Apolipoprotein E (APOE), which 
is found in chylomicrons and IDLs, is necessary for the transport of fats through the blood. APOE 
is transcriptionally activated by LXRs and RXRs. Upregulated APOE is associated with 
suppressed metastasis in melanoma cancer cells [62]. Therefore, Studies of LXR ligands in 
colon, breast, prostate, lung, and skin cancer cells indicate a potential role for these ligands and 
LXRs in cancer cell proliferation [63].  
Knockout animals provide a starting point to ascertain what roles the LXRs play in 
carcinogenesis. Female mice lacking LXRβ spontaneously undergo a process of gallbladder 
transformation suggesting a specific role of this receptor in regulating carcinogenesis [64]. There 
are also roles for LXRβ in the pancreas, as LXRβ knockout mice have reduced lipase, amylase, 
and protease secretion into the upper intestine, resulting in pancreatic insufficiency and 
malabsorption. This abnormality is also accompanied by large infiltration of immune cells in the 
pancreatic ducts, possibly because of LXR’s known roles in suppressing inflammatory responses. 
Examination of the tissue sections revealed pancreatic ducts reminiscent of chronic pancreatitis 
in humans, a risk factor for pancreatic cancer. In these particular mice, there was no difference in 
cell proliferation between wild-type and knockout mice, but there was increased apoptosis in the 
pancreatic ducts. An antiproliferative effect of LXR ligands we recently demonstrated in pancreas.  
A low dose of GW 3965 was potentiated by treatment with 9-cis-retinoic acid in pancreatic islet 
cells [65]. These studies, however, were carried out in non-transformed cells. The effect of LXRs 
on malignancy in the pancreas of exocrine duct origin has not yet been explored, and represents 
a unique opportunity to explore the roles of nuclear receptor ligands in pancreatic ductal 
adenocarcinoma. 
1.2.4 Pancreatic Ductal Adenocarcinoma and Currently Approved Therapies 
 
The pancreas is a key organ involved in digestion and blood sugar regulation, and is 
subject to a wide variety of pathological conditions, which are known to dramatically reduce the 
quality and length of life. Pancreatic cancer is an umbrella term used to describe malignancies 
derived from cells in the pancreas, and is composed of several different subtypes with varying 
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outcomes and prognoses[66]. Pancreatic ductal adenocarcinoma (PDAC) is the most common 
type of pancreatic cancer, and originates from the ductal cells that carry digestive enzymes and 
basic solutions to the intestines. Pancreatic neuroendocrine tumors (i.e. insulinomas) arise from 
cells in the Islet of Langerhans, and are less common and more treatable pancreatic cancers [67]. 
Malignant tumors derived from pancreatic acinar cells are relatively rare when compared to 
PDAC (~5%) as well. Cancers of the pancreatic ductal cells (PDAC) are highly resistant to 
available therapeutics, with a combined survival rate of 5% after five years regardless of the initial 
stage of the pancreatic cancer at the time of diagnosis [68]. PDAC is an aggressive and resistant 
cancer, often failing to respond to the standard-of-care chemotherapeutic gemcitabine, a cytidine 
nucleoside analog that blocks DNA replication. Approximately 20% of the diagnosed cases of 
PDAC are resectable with the intention of curing the cancer [69]. As many of these cancers arise 
in the “head” of the pancreas, a patient may undergo an operation to remove the duodenum and 
the gallbladder in addition to the head of the pancreas due to a shared blood supply [70,71]. The 
tail of the pancreas and the stomach are then reattached to the jejunum. Such a dramatic 
remodeling of the digestive system is more or less tolerated depending on the amount of 
pancreas removed. Patients with extensive pancreas removal may not produce enough digestive 
enzymes to properly break down food particles, and may also experience mild diabetes. These 
surgical procedures are risky and very complicated due to individual variations in the 
configuration of the main pancreatic ducts.  
Malignant PDAC tumors are thought to be derived from pancreatic intraepithelial 
neoplasias (PanIN), which are positively correlated with age and chronic pancreatitis [72].  
PanINs are found mostly in the head of the pancreas [73]. In post-mortem autopsies, PanINs 
were remarkably common, and are divided into different stages, representing different levels of 
dysplasia [74]. PanIN-1 lesions are histologically columnar that have maintained polarity. Cells 
that have lost cell polarity and contain hyperpigmented nuclei of variable size are referred to as 
PanIN-2. The most complex lesions are PanIN-3 grade, which contain cell nuclei that are 
enlarged and lack orientation [74]. Structurally, these cells form papillae, with epithelial buds 
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protruding into the ductal lumen. Mutations leading to higher-grade neoplasias are thought to be 
acquired sequentially, albeit there are no exact or preordained routes leading to high grade 
PanINs [72]. For instance, KRAS2 hyperactivation leads to increased cell division and extensive 
telomere shortening, and is thought to be an early event in dysplasia leading to PanIN-1. 
p16/CDKN2A is then lost, leading to the development of PanIN-2 lesions. Bi-allelic loss of P53 
tumor suppressive activity is associated with the development of PanIN-3. Many of these genes 
have known roles as tumor suppressors or oncogenes, thereby supporting the notion that PanINs 
are early pancreatic cancers.  
After the resection and remodeling of the remaining pancreas, patients undergo rounds of 
chemotherapy after sufficient recovery time (1-2 months). A majority of patients (~80%) are not 
eligible for surgical resection due to the advanced nature of the disease at the average time of 
diagnosis, but are offered chemotherapy to extend lifespan and to improve the quality of life [69]. 
Gemcitabine, the standard chemotherapeutic for pancreatic cancer, was found to be more 
effective that 5-fluoruracil, another nucleotide analog that introduces double stranded breaks into 
the DNA of rapidly dividing cells [75]. Gemcitabine improves median survival just over one month 
when compared to 5-fluorouracil [76], and was the first chemotherapeutic agent ever approved by 
the FDA based on parameters other than the survival endpoint. Recent advances in PDAC 
treatment paired gemcitabine with EGFR inhibitors, such as erlotinib or cetuximab [77,78].  
Erlotinib marginally improves the median survival by only two weeks.  EGFR inhibitors are 
typically used in patients with overexpressed or mutated EGFR in a variety of different cancers.  
The success of EGFR therapy is dependent upon an unmutated/wild-type KRAS due to 
constitutive growth factor signaling independent of and downstream of EGFR with mutated 
KRAS. In general, EGFR inhibitors have been shown to be subject to the rapid development of 
resistance approximately 10 months after treatment initiation, and by themselves, do not 
represent a viable strategy for the treatment of cancers in the long term [79].  Therefore, 
alternative strategies other than those currently approved are needed to improve the survival and 
quality of life of pancreatic cancer patients. Data that demonstrate the antiproliferative effects of 
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the LXRs in other tissues represent potential treatment avenues in the treatment of pancreatic 
cancers. The associated study is presented in Chapter 2.  
 
 
1.3 Introduction: Mechanisms of ERs in Breast Cancers1  
1.3.1 Estrogens and Estrogen Receptors: The Initial Characterization of Estrogen  
 
The female steroid hormone estrogen has pleiotropic effects on human development, 
physiology, and a number of endocrine-related conditions and diseases [80-82]. Initially, estrogen 
was thought to be involved in cellular redox reactions through interactions with coenzymes[83]. A 
competing hypothesis suggested that cells in target tissues may harbor receptor molecules 
whose presence would dictate tissue-specific responses [84]. Jensen and Jacobson developed a 
method to tritiate estradiol, the predominant form of estrogen, and showed that radiolabeled 
hormones were functional, accumulated in estrogen-responsive reproductive tissues, and were 
not chemically altered [85]. Studies by Gorski et al. and also Jensen et al. went on to demonstrate 
that estrogen was bound to proteins in the cytoplasm that subsequently localized to the nucleus 
of target cells and activated the synthesis of specific transcripts [86-89]. Jensen termed the 
estrogen-binding protein estrophilin, whereas Gorski referred to the protein as the estrogen 
receptor (ER) [90,91]. Molecular characterizations of ER became possible when the ER gene was 
cloned by the Chambon group [92]. Mutagenesis studies showed that the receptor consists of a 
DNA-binding domain containing zinc finger motifs and a ligand-binding domain, key structural 
elements of a ligand-dependent transcription factor [93]. Other related receptors, including the 
glucocorticoid receptor, the thyroid hormone receptor, and the progesterone receptor, were also 
cloned and characterized around the same time [94-97]. A second closely related ER with similar 
affinity for estradiol but distinct tissue specificity and affinity for other estrogenic compounds was 
discovered by Gustafsson and Kuiper and was subsequently named ERβ, and the original ER 
was renamed ERα [98]. The roles of ERα and ERβ in mediating estrogen response in normal 
                                                       
1 Contents in this chapter have been previously published as “Estrogen receptor alpha: Molecular 
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physiology and in diseases have been subjected to intense investigation. An orphan G protein-
coupled receptor (GPR30) was also reported to function as an ER, but these observations have 
been disputed by more recent hormone binding and genetic studies [99].  
 
1.3.2 Transcriptional Regulatory Mechanisms of ER 
Upon activation by ligand, ERα dimerizes and binds directly to cis-regulatory regions of 
target genes via conserved estrogen response elements (EREs; consensus 5′-
GGTCAnnnTGACC-3′) [100]. ER can also be tethered to other transcription factors such as AP-1, 
Sp1, and NFκB to indirectly influence gene expression [101-103] (Figure 4.1B-C). Structural 
changes induced by ligand binding to ERα facilitate the formation of nuclear receptor co-regulator 
binding surfaces which then complex SWI/SNF ATP-dependent nucleosome remodeling 
enzymes that enable necessary changes to histone spatial position and co-activators which 
include histone modifying enzymes such as histone acetyl-transferases (HATs: P300/CBP, 
P/CAF, SRC-1, and p/CIP/AIB1), histone methyl-transferases (HMTs: CARM1 and PRMT1), and 
histone ubiquitin ligases (RPF1 and E6-AP) [5,104]. Co-repressors, such as NCoR, NRIP1, and 
SMRT recruit histone deacetylases (HDACs) and have been shown to bind to ERα in the 
presence of antagonists or at specific cis-regulatory regions of repressed target genes following 
hormone activation [105-107]. These interactions and mechanisms are summarized in Figure 1.2. 
 Once the proper histone modifications are made at the target gene promoter orchestrated 
by ERα-bound coactivators, TFIID/TBP is stabilized at the promoter by TFIIA. TFIIB then binds 
and positions RNA polymerase II at the correct initiation site [108]. Signaling of TFIIH by the 
TRAP/mediator complex stimulates phosphorylation of the C-terminal domain of the polymerase 
leading to transcription initiation and elongation. SWI/SNF is typically maintained at the promoter 
as the cells utilize this complex to modify histone spatial configuration in preservation of active 
transcription in the presence of ERα, but also to discontinue that configuration once estrogen 
response is uncoupled [109]. After co-activator assembly, members of the ubiquitin proteasome 
pathway regulate degradation of portions of the preinitation complex so that elongation is possible 
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[6]. Treatment of estrogen-responsive cells with proteasome inhibitors interrupts the cyclic 
association of co-regulator proteins with the ERα complex, which eventually results in the loss of 
phosphorylated polymerase II. ERα itself is subjected to a variety of post-translational 
modifications which result in changes in receptor stability and activity in response to specific 
ligands and signaling events in the cell [110]. 
 
1.3.3 Non-genomic Actions of Estrogen Receptor  
ERα is predominantly studied as a ligand-dependent transcription factor, but early work 
demonstrated that estrogen has rapid effects on cell signaling [111-114]. These effects suggested 
the existence of signaling pathways not mediated by transcriptional regulatory mechanisms. 
Estrogen rapidly signals ERα/G protein complexes through secondary messengers calcium and 
cAMP, activated PI3K, and activated RAS [113]. Some ERα appear to localize to the cytoplasm 
and interact with growth factor receptors (GFRs) such as EGFR and IGF-1R. Activation of these 
receptors through ERα is thought to stimulate GFR effector kinases and their downstream targets 
such as PI3K and ERK. Activation of PI3K by GFR/ERα signaling results in the inhibition of GSK-
3β, which is known to phosphorylate ERα S118 and inhibit its activity. This allows for amplified 
ERα transcriptional activity in the nucleus [112]. It is through these GFR effector signals that 
estrogen is able to upregulate cyclin D1 expression, thereby promoting G1/S transition through 
the cell cycle. 
ERα is believed to be tethered to the cytoplasmic membrane through one or a 
combination of different mechanisms, such as association with lipid-raft proteins like caveolin-1 or 
by direct interaction with GFR complexes [114,115]. Interaction of ER with caveolin-1 and the cell 
membrane requires palmitoylation of ERα [116]. Interestingly, this modification is required for 
signaling ERK and PI3K pathways. Recent experiments have attempted to characterize a 
separate membrane bound receptor for estrogen, as almost all ER is found in the nucleus. In fact, 
membrane bound ER was thought to be GPR30. However, knockdown experiments failed to 
prevent ERK activation after estrogen stimulation, raising questions about the significance of this 
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finding [117]. Several lines of evidence suggest that membrane-bound ER appears to be the 
same ERα and ERβ found in the nucleus [113]. The non-genomic mechanisms of ERα action are 
depicted in Figure 1.2. 
 
1.3.4 Novel Transcription Factor Binding Partners 
The genome-scale ERα binding site mapping studies yielded a large amount of positional 
and sequence data and provided rich datasets for computational modeling and analysis of 
sequence motifs associated with ERα binding. For example, motif analysis confirmed the 
previously defined ERE consensus sequence motif [118,119]. Furthermore, other sequence 
motifs are enriched in the proximity of ERα binding sites and suggest potential physical and 
functional interactions between ERα and other transcription factors. The first chromosome-wide 
mapping studies revealed an enrichment of binding site motifs for Forkhead factors [120]. This 
enrichment was subsequently confirmed by genome-wide mapping studies [118]. Forkhead family 
member FOXA1 was previously identified as an ERα interacting protein and was shown by 
Carroll et al. to be the Forkhead factor which localize to the proximity of ERα binding sites and 
serve as a pioneering factor which potentiate ERα binding and transcriptional activity. FOXA1 
appears to play key roles in hormone-dependent tumor growth and response to endocrine 
therapy in breast cancer and has similar roles in prostate cancer through its interactions with the 
androgen receptor [121,122]. In another study of binding site motifs associated with ERα binding 
sites, Kong et al. identified the transcription factor GATA3 as a component of an enhanceosome 
which includes both ERα and FOXA1, and this complex is involved in optimization of 
transcriptional responses to estrogen treatment [123]. Interactions between GATA3 and ERα also 
involve a cross-regulatory mechanism by which each of these factors regulates the expression of 
the other through direct binding of cis-regulatory regions of their partners [124]. Related to these 
molecular interactions, GATA3 has established roles in mammary gland development and its 
expression is highly correlated with ER-status in breast tumor tissues [125,126]. In a follow-up 
study to the ERα-promoter interactome mapping paper, Tan et al. identified AP-2 binding site 
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motifs in ERα binding sites which are involved in long distance looping structures and showed 
that AP-2γ is a collaborative factor in interactions involving ERα, FOXA1, and promoter regions 
of target genes [127]. AP-2γ functions in hormone response in breast cancer cells and its 
expression levels are elevated in tumors with poor clinical outcomes [128,129].   
Adding to the rapidly accumulating datasets and insights, Stender et al. carried out a 
genome-wide ERα binding site study using an ERα construct with mutations in the DNA-binding 
domain specifically designed to detect tethering mechanisms and factors [130]. They showed that 
in addition to the binding site motif of the AP-1 complexes, known to tether ERα to DNA, there is 
an enrichment of binding site sequence motifs for runt-related transcription factors. They also 
provided evidence that RUNX1, specifically, binds ERα and regulates the expression of a subset 
of estrogen-responsive target genes. RUNX1 has been well studied for its roles in hematopoiesis 
and regulation hematopoietic stem cell differentiation. RUNX1 is implicated in leukemogenesis 
and is frequently mutated in malignant myeloid cells, and there is increasing evidence for its role 
in breast cancer [131,132]. Interestingly, a genetic study in mice examining strain-specific 
uterotropic responses to estrogen treatment identified quantitative trait loci which included the 
locus for the Runx1 gene and showed a correlation between Runx1 transcript and protein 
expression levels and response to hormone treatment [133]. The transcriptional mechanisms of 
ERα action are depicted in Figure 1.2B-C. 
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Figure 1.1 Mechanisms of action of ERα in the nucleus and cytoplasm of a target cell.  
(A) Genomic and non-genomic actions of estrogen receptor. (B) Direct DNA binding activity of 
estrogen receptor to EREs. (C), (D) Tethering of ER to alternative transcription factors throughout 
the genome.  
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1.3.5 Breast Development  
 The breast is composed of glandular and parenchymal tissue (stromal cells). The non-
parenchymal breast is composed of ducts and lobules, which produce milk that is channeled into 
the ducts. Myoepithelial cells surround the ductal cells, and contract during lactation to promote 
movement of secreted milk throughout the duct system. The first observable mammary structures 
are termed the milk lines, which are specified by Wnt10b [134]. Followed by this, placodes are 
specified, and are programmed to invaginate the mesenchymal tissue underneath them by 
FGF10 and BMP4 [135]. Parathyroid hormone-related protein (PTHrP), which is secreted from 
the mammary bud, regulates BMPR1A in the mammary mesenchymal cells, thereby sensitizing 
them to BMP4 signalling [136]. Activated BMP4 signaling in the mammary mesenchymal cells 
regulate the invasion of the epithelial and mesenchymal mammary cells into the fat pad 
precursors. At this point, this structure arrests invasion until puberty, which is primed to further 
elongate into the fat pad dependent upon estrogen signaling.  Gata3 has been shown to be 
important for terminal end bud formation, which in combination with FOXA1, potentiate breast-
specific targets of ERα [125]. Terminal end buds do not form and do not invade when ERα or 
Gata3 are attenuated. During puberty, EGF, estrogen, and CSF1 mediate the elongation and 
invasion of tubular ducts past the lymph nodes until the end of the mammary fat pad [137]. 
Terminal end buds (TEBs) are found at the ends of these ductal structures. During early 
pregnancy the terminal end buds no longer proliferate, but are programmed to develop side 
branching alveoli. This transformation is regulated by GATA3, prolactin, and progesterone 
receptor (PR). Side branching is attenuated in PR knockout models. Upon childbirth, the luminal 
cells are able to generate milk. Lactation is promoted by GATA3, prolactin, and STAT5A/B. 
Expanded breast tissue is involuted upon weaning, which results in the ordered apoptosis of 
breast tissue back to the pubertal size.  
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1.3.6 Breast Cancer Subtypes and Treatments  
The invasive nature of the breast placode in early specification suggests that there are 
developmental pathways that are often reactivated constitutively by cancers. Advances in 
genome-wide sequencing in the new millennia has allowed for the characterization of individual 
tumors based on gene expression. Four major types of breast cancer have been identified based 
on these gene expression profiles: Estrogen receptor α, progesterone receptor, HER2 expression 
levels, and Ki67 expression levels. First, ER expression confers a better prognosis and an 
additional panel of drugs to treat them [138,139]. ER dependent cancers are treated with 
selective estrogen receptor modulators (SERMs), which are designed to attenuate estrogen 
dependent cell proliferation. ER+ breast cancers are also treated with aromatase inhibitors, 
compounds that prevent de novo synthesis of estrogens within the breast cancer itself [51]. 
Second, progesterone receptor, which regulates branching morphogenesis in lactation, is 
predictive of a normally functioning ERα and response to SERM compounds [140]. Thirdly, 
HER2/ERBB2 is a cell surface growth factor receptor that is overexpressed in 30% of breast 
cancers [141]. Hyperactive HER2 signaling results in increased MAPK signaling, markers that are 
known to decrease the antiproliferative effects of SERMs. These receptors are attenuated by 
monoclonal antibodies, such as trastuzamab and pertuzumbab, which are approved for the 
treatment of HER+ breast cancers. Lastly, Ki67 staining is a well-established marker for cell 
proliferation, and its expression levels are negatively correlated with survival and response to 
therapy [142]. These markers allow for the tailoring of treatments to attain the best possible 
outcomes with currently available therapeutics.  
Breast cancer cells express these four markers in different arrangements or 
combinations. This configuration largely determines their response to different therapies, and may 
also denote the cellular origin of the malignancy. Cancers that are ER+/PR+/HER2-/Ki67low are 
categorized as luminal A breast cancers. This molecular subtype represents 40% of the 
diagnosed cases, has the best prognosis of the explored cancers, and resembles cells that line 
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the lumen of the mammary duct [138,139]. These cancers are treated with endocrine therapy and 
have relatively low recurrence. The luminal B subtype is ER+/PR+/HER2+/Ki67low or 
ER+/PR+/HER2-/ Ki67high and represents 20% of the diagnosed breast cancer cases [138,139]. 
These cancers are also derived from the cells lining the mammary ducts, but proliferate more 
rapidly, and therefore are characterized by less favorable outcomes than luminal A breast 
cancers. Triple negative breast cancers are ER-/PR-/HER2- and encompass 20% of diagnosed 
breast cancers. Triple negative cancers are derived from cells that surround the mammary ducts, 
and usually bare p53 mutations, which are predictive of poor response to therapy [138,139]. 
These cancers are limited to chemotherapeutics due to the lack of the targetable markers 
mentioned earlier. Triple negative cancers are associated with a poor prognosis when compared 
to luminal A and B. Lastly, the HER2 type is ER-/PR-/HER2+ and is found in the remaining 10-
15% of diagnosed women [138,139]. These cancers also have a poorer prognosis than luminal A 
and luminal B, but can be targeted with trastuzamab, which leads to decreased cell proliferation. 
These different breast cancers represent major subtypes, and are each predisposed by different 
genetic, environmental, and behavioral factors.  
Risk factors for the development of breast cancer are first a foremost, older age and 
female sex. Cancer is thought of as a disease of aging, as mutations accumulate in cells 
throughout the body, the chances of a cell acquiring the correct mutations and the precise 
environmental conditions increase. Female sex predisposes women to cancer due in large part to 
the presence of estrogen, which regulates the development of the breast duct [143]. Excessive 
levels of estrogen, early puberty, or hormone replacement therapy for women in menopause, are 
known to increase the risk of breast cancer [144]. Secondary to these are dietary, genetic, and 
behavioral factors. Mutations in several genes have been shown to dramatically increase the risk 
of breast cancer. The most potent, however, is BRCA1, a tumor suppressor involved in DNA 
damage repair. Mutations in this gene result in a hereditary breast-ovarian cancer syndrome 
[145]. These women are at incredible risk of several malignancies, as high as 80% will develop 
breast cancer by the age of 90 [146]. BRCA1 mutations also predispose women to an increased 
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risk of ovarian cancer (~25%). Modifiable behavioral factors such as alcohol consumption have 
been shown to increase the risk of breast cancer. Epidemiological studies have strongly linked 
alcohol consumption to increased breast cancer risk [147-150]. These epidemiological studies, 
therefore, will attempt to more clearly link alcohol with measurable phenotypes in cell-based 
assays as a means to clearly identify mechanisms of alcohol action in breast cancer cells. These 
studies are presented in Chapter 3.  
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2. Antiproliferative Effects and Mechanisms of Liver X 
Receptor Ligands in Pancreatic Ductal 
Adenocarcinoma Cells2 
2.1 Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly cancers, with a 
combined (all four stages) survival rate of 5% after five years [68]. Localized neoplasms represent 
about 20% of diagnosed cases and are resected using the Whipple procedure [69]. PDAC is 
often asymptomatic until the disease is late in its progression and tends to be poorly vascularized 
and resistant to the standard-of-care chemotherapeutic gemcitabine, a cytidine nucleoside analog 
that blocks DNA replication [75]. Gemcitabine improves median survival just over one month 
when compared to 5-fluorouracil [76]. Recent advances in PDAC treatment paired gemcitabine 
with EGFR inhibitors, such as erlotinib or cetuximab, and this combination improved median 
survival by less than two weeks [77,78].  Alternative strategies are clearly needed to improve 
survival and quality of life for PDAC patients. 
Members of the nuclear receptor (NR) superfamily of ligand-dependent transcription 
factors carry out vital cellular functions and are highly druggable targets [151]. NRs are 
modulated by steroidal and non-steroidal compounds in maintenance of normal metabolism, 
development, and immune responses [2,152]. Because NRs have ligand-binding domains with 
highly specific binding pockets, they can be targeted by a plethora of synthetic compounds in the 
treatment of autoimmunity, diabetes, and hormone-dependent malignancies of the breast and 
prostate [2,152]. For example, estrogen receptor plays a key role in breast cancer and is targeted 
by selective estrogen receptor modulators (SERMS) in the prevention and treatment of hormone-
dependent breast cancers [153]. The androgen receptor is similarly targeted in the treatment of 
prostate cancers. 
                                                       
2 This chapter of the thesis has been previously published as the “Antiproliferative Effects and 
Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells” in PloS 
One, 9(9), e106289. 
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Liver X receptors (LXRs) are members of the nuclear receptor superfamily and have 
been studied extensively for their roles in regulating cholesterol, glucose, fatty acid metabolism, 
and inflammatory related pathways [2]. Two isoforms have been described, LXRα and LXRβ, that 
despite common characteristics (high homology in sequence, heterodimerization with 9-cis 
retinoic acid receptors, and a similar ligand profile) have distinct and specific functions [154]. 
LXRs are activated by a variety of endogenous ligands in normal homeostasis (27-
hydroxycholesterol, 20(S)-hydroxycholesterol), or by synthetic ligands such as GW3965 or 
T0901317 that were developed for the treatment of atherosclerosis. Recent studies in rodents 
have shown that LXRβ is strongly expressed in pancreatic ductal epithelial cells and LXRβ-/- 
mice develop a severe pancreatic exocrine insufficiency [12]. However, it is not know whether 
LXRβ or its ligand may affect normal exocrine pancreatic function or the development of 
malignancies in humans. Studies of LXR ligands in colon, breast, prostate, lung, and skin cancer 
cells indicate a potential role for these ligands and LXRs in cancer cell proliferation [63]. 
Treatment of LNCaP prostatic cells with LXR agonists suppressed their growth in xenograft 
models [54]. LXR agonists are also antiproliferative in breast cancer cell lines by disrupting both 
estrogen-dependent proliferation and cell cycle machinery [55,56]. In addition, female mice 
lacking LXRβ spontaneously undergo a process of gallbladder carcinogenesis suggesting a 
specific role of this receptor in regulating cell proliferation [64]. Interestingly, an antiproliferative 
effect of LXR ligands is potentiated by treatment with 9-cis-retinoic acid in pancreatic islet 
cells[65]. Based on these observations, we hypothesized that LXR ligands may block cancer cell 
growth in PDAC. In this study, we examined the effects of LXR agonists on PDAC cells and 
identified potential mechanisms of action.    
 
2.2 Materials and Methods 
2.2.1 Ethical Statement 
De-identified human samples utilized in the study were obtained from the Texas Cancer 
Research Biobank (http://txcrb.org/index.html) that collected the samples following patient 
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consent and collection protocol (H-29198) approved by the Baylor College of Medicine 
Institutional Review Board. The use of the tissues by the authors was exempt from institutional 
review as confirmed by the University of Houston Institutional Review Board. 
2.2.2 Immunohistochemistry 
Representative sections (n=8) of pancreatic adenocarcinoma were obtained from Texas 
Cancer Research Biobank. 4 males and 4 females were studied (age 40-69). Sections were 
dewaxed in xylene and rehydrated through graded ethanol. After antigen retrieval with PT module 
(Thermo Scientific) for 17 minutes at 97 °C, sections were incubated in 3% H2O2 in 50% methanol 
for 30 min at room temperature to quench endogenous peroxidase. To block nonspecific binding, 
sections were incubated in PBS containing 1% BSA and 0.1% Nonidet P-40 for 1 h at room 
temperature. Primary antibody reactions were incubated at 4 °C overnight. Goat anti-LXRβ and 
anti-LXRα antibodies were developed as previously described [12,155] and used at 1:50 dilution 
in 1% BSA and 0.1% Nonidet P-40. Negative controls were incubated with PBS containing 1% 
BSA and 0.1% Nonidet P-40 without primary antibody. After washing, sections were incubated 
with goat-probe (Biocare Medical, GHP516) for 15 minutes, then washed in PBS and incubated 
with goat-on-rodent-HRP polymer (Biocare Medical, GHP516) for 15 minutes. After washing in 
PBS, sections were developed with 3,3'-diaminobenzidine tetrahydrochloride substrate (DAKO) 
and then counterstained with Mayer´s hematoxylin. Sections were dehydrated through a graded 
ethanol series and xylene and finally mounted.  
 
2.2.3 Cell Lines and Tissue Culture 
Three human pancreatic cancer cell lines were selected for these studies, BxPC-3, MIA-
PaCa-2, PANC-1, (American Type Culture Collection, Rockville, MD, USA). MIA-PaCa-2 and 
PANC-1 were grown in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) 
containing high Glucose with HEPES and supplemented with 10% fetal bovine serum. BxPC3 
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cells were cultured in DMEM F-12 (Invitrogen), containing HEPES and Glutamine and 
supplemented with 10% FBS (Hyclone, Logan, UT, USA). 
 
2.2.4 Cell Treatments, Gene Knockdowns, and Cell Proliferation Assays 
Cells were treated with GW3965 (Tocris Bioscience, Bristol, UK), T0901317 (Tocris 
Bioscience, Bristol, UK), gemcitabine (Sigma-Aldrich, St. Louis, MO, USA) at indicated 
concentrations or ethanol as a vehicle. Cell proliferation was measured by MTS metabolic rate 
assays using CellTiter96® AQueous One Solution (Promega, Madison, WI, USA) following 
manufacturer’s protocol or standard trypan blue exclusion assays using the Countess automated 
cell counter (Invitrogen) or hemocytometer. Experiments were performed in triplicate. LXR 
knockdown experiments were performed by transfecting PDAC cells with pooled targeting siRNA 
against LXRα and LXRβ following manufacturer’s (Thermo Scientific Dharmacon, Lafayette, CO, 
USA) protocol. Transfections with scrambled siRNA were included as negative controls.  
 
2.2.5 Cell Cycle Analysis and BrdU Incorporation Assays 
Cells were treated with 10 µM GW3965 for 72 hours and then pulsed with 10 µM BrdU for 
1 hour. Treated cells were then trypsinized and fixed in 70% ethanol and stored at -20° C for 24 
hours. DNA was denatured in 2 M HCl/0.5% Triton-X and then neutralized in 100 mM sodium 
borate. FITC-conjugated anti-BrdU antibody was then added to bind incorporated BrdU. Fixed 
cells were incubated at 37°C for 30 minutes with 50 µg/ml of propidium iodide and 10 µg/ml 
RNase A. FACS Aria 111 Cell Sorter (BD Biosciences) utilized for data collection, and the data 
were analyzed using FlowJo software program.  
 
2.2.6 Clonogenic Assay 
Cells were seeded in 100mm plates and treated with LXR ligand for one week (MIA-
PaCa-2) or two weeks (BxPC-3 and Panc-1). At the end of treatment period, cells were washed 
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with PBS and fixed in 4% formaldehyde and washed again with PBS. Colonies were then stained 
with crystal violet (Sigma-Aldrich), scanned, and quantified using the Clono-Counter software 
[156]. 
 
2.2.7 Microarray and Data Analysis 
 Total RNA from each cell-line was isolated using RNeasy columns (Qiagen).  
The Illumina TotalPrep-96 RNA Amplification kit was used to convert 250 ng of RNA to 
cRNA (Ambion, Carlsbad, CA, USA). Then, cRNA was hybridized to the Illumina Whole-
Genome Gene Expression Direct Hybridization microarray (Illumina, San Diego, CA, 
USA). Probes that detect multiple genes were eliminated.  The R software packages lumi 
and limma were used to calculate differentially expressed genes in treated cells. Intensity 
values were normalized and log-2 transformed. The Benjamini-Hochberg correction was 
used to correct for potential false discovery. A 1.1 fold change cutoff was then used to 
generate a list of responsive genes for data mining.  Bioinformatic analyses of enriched 
gene sets were made in Pathway Studio (Ariadne Genomics, Rockville, MD).  Fisher’s 
exact test was applied to determined significantly enriched pathways. Transcription factor 
(TF) target enrichment, gene ontology (GO) categories, and Ariadne Pathway Categories 
used were provided within the software. The microarray data have been deposited with 
the Gene Expression Omnibus repository and will be available for public access following 
publication (accession number GSE51656). 
 
2.2.8 Quantitative PCR 
 RNA was extracted using a Qiagen RNeasy kit then reverse transcribed using 
SuperScript III reverse transcriptase system (Invitrogen). Quantitative PCR was then 
performed using Fast SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA, USA) 
on a 7500 fast real-time PCR system (Applied Biosystems). Primers for these genes 
were designed using Primer BLAST. These are listed in Table 2.1. Fold changes were 
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calculated using the ΔΔCt method normalized to 36B4, a housekeeping gene (36B4 
forward, 5’-GTGTTCGACAATGGCAGCAT-3’; 36B4 reverse, 5’-
GACACCCTCCAGGAAGCGA-3’).  
2.2.9 Western Blot Analysis 
 Cells were serum starved 24 hours prior to treatment and restoration to normal medium. 
Ligand-treated cells were lysed in RIPA lysis buffer. Protein concentrations were measured using 
Qubit Protein Assay Kit (Invitrogen). 50 µg of protein was loaded into standard 10% 
polyacrylamide gels. After protein separation, SDS-PAGE gels were transferred to PVDF 
membranes (Millipore, Billerican, MA, USA). Membranes were then blocked in 10% nonfat milk 
dissolved in TBST than probed with antibodies directed against LXRα (proprietary, C. Gabbi), 
LXRβ (GeneTex Cat no. 89661), Skp2 (Santa Cruz sc-7164), EGFR (Santa Cruz sc-03), 
phospho-EGFr (Tyr1173) (Invitrogen 18-2465), ERK1/2 (Cell Signaling 9102), phospho-ERK1/2 
(Thr202/Try204) (Cell Signaling 4377),or β-actin (Sigma-Aldrich A2228) in 1% milk overnight. 
Membranes were then washed of unbound antibody and reprobed with secondary antibodies 
conjugated to horseradish peroxidase (HRP) for at least 1 hr. HRP bound antibodies were then 
exposed to ECL reagent (Thermo Fisher Scientific, Rockford, IL, USA), which allows for their 
detection by film. Fold change quantification was determined by densitometric analysis available 
in ImageJ software. 
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Table 2.1 Primers used in this chapter 
Gene Forward Reverse 
RFC2 5’-CAGCAAGCCTTGAGGAGAA-3’ 5’-GCACAGCGGGACTGAATG-3’ 
CLSPN 5’-ACGGTTTACTCTGGATAGA-3’ 5’-TCACCTCTGTTGGTTTCA-3’ 
PKIA 5’-CTGGACAAATAGCAGACAATG-3’ 5’-CTGGCACAACCACACAAA-3’ 
MCM3 5’-GTCTGTGTGGAGGGCATTG-3’ 5’-CGTCGCTCTATGGTCTTCTT-3’ 
JAG2 5’-TCAGAGGCAAGGTCAGCATTT-3’ 5’-CAAGCAGTGAGGGGCAAAAC-3’ 
STAT3 5’-CAGCAGGAGGGCAGTTTGA-3’ 5’-TGTGAGGGGTGGCAGAATG-3’ 
ZWINT 5’-TCTGGCGGAGGTTTCT-3’ 5’-GCTGCTGGGGTTTATCAT-3’ 
SKP2 5’-CCCAGGAACTGCTCTCAAA-3’ 5’-CTGCGGACAATCACAAAGT-3’ 
YWHAB 5’-CTGGGGAGGGAGAGAACTA-3’ 5’-GGCTGAGGCTGTGAAAAA-3’ 
BIRC3 5’-CCAAGTGGTTTCCAAGGTGTG-3’ 5’-TCATCTCCTGGGCTGTCTGA-3’ 
PRIM 5’-AATATGGACCCTGGCTGGAG-3’ 5’-GCACAGATATGCGACCTGTT-3’ 
STAT1a 5’-CGACAGTATGATGAACACAGTA-3' 5’-AGAGTAGCAGGAGGGAATCA-3’ 
STAT1b 5’-ACCAGAGCCAATGGAACTT-3’ 5’-CATGTCACTCTTCTGTGTTCA-3’ 
POLA1 5’-GCGACGACTCTCTGTCAGATT-3’ 5’-TCTTTCTAGGGCTTCTTGGCG-3’ 
SREBF1 5’-GGCACCGAGAGCAGAGATGGC-3’ 5’-GGAGACGAGCACCAACAGCCC-3’ 
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2.3 Results  
2.3.1 Expression of LXR Isoforms in Pancreatic Cancer Cells and Clinical Samples 
 
Before characterizing the effect of LXR ligands on pancreatic cancer cell biology, which 
we hypothesize will restrain proliferation-related processes; we first examined LXRα and LXRβ 
expression in biopsies of human pancreatic cancer and PDAC cell lines. Immunohistochemical 
staining of LXRβ in human samples demonstrated nuclear immunoreactivity in normal pancreatic 
ducts (Figure 2.1A). Nuclear and cytoplasmic LXRβ immunoreactivity was detected in PDAC 
samples (Figure 2.1B-C), suggesting altered localization of LXRβ in these cancerous samples. 
Comparatively, LXRβ expression was barely detectable in a pancreatic adenoma clinical sample 
(Figure 2.1D). Immunostaining for LXRα was not detectable both in normal ducts (Figure 2.1E) 
and in a PDAC sample (Figure 2.1F). These results suggest that LXRβ is the main isoform 
present in pancreatic ductal epithelial cells and its abnormal localization is evident in PDAC 
patient tissues.  
For functional studies, BxPC-3, MIA-PaCa-2, and PANC-1 PDAC cell lines were chosen 
for characterization because they exhibit different invasive, proliferative, and angiogenic potential 
[157].  Western results indicate that LXRβ was detected in BxPC-3 and MIA-PaCa-2 and PANC-1 
cells, although expression levels were the lowest in the PANC-1 cells (Figure 2.1G). Consistent 
with our observations in clinical samples, LXRα was not detected in PDAC cell lines (Figure 
2.1H).  LXR agonist GW3965 also activated expression of ABCA1, a known LXR target gene [55], 
in all three cell lines (Figure 2.11). These findings indicate that LXRβ is expressed and functional 
in PDAC cells. 
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Figure 2.1. LXRβ is the main LXR isoform expressed in pancreatic cancer samples and in 
three pancreatic adenocarcinoma cell lines.  
(A) LXRβ was detected in the nuclei of normal pancreatic ductal epithelial cells (female, age 59).  
(B) (C), LXRβ positive immunoreactivity was evident in both the cytosol and the nuclei of 
neoplastic cells of patients with pancreatic adenocarcinoma (male, age 59 and female, age 65 
respectively. (D), LXRβ expression was undetectable in the pancreatic adenoma sample (female, 
age 59). (E), (F) LXRα immunoreactivity is not detectable in normal ductal epithelial cells (female, 
age 59) and in pancreatic adenocarcinoma (male age 65). (G), LXRβ is expressed in BxPC-3, 
Mia-PaCa-2, and PANC-1 cells. H, LXRα is not expressed in PDAC cell lines.  Scale bar=50µM.   
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2.3.2 Anti-proliferative Effects of LXR Ligands 
To determine the effects of LXR ligands on PDAC cell proliferation, cells were treated 
with synthetic LXR agonist GW3965 and live cells were quantified using trypan blue exclusion 
assays. BxPC-3 (Figure 2.2A), MIA PaCa-2 (Figure 2.2B), and PANC-1 (Figure 2.2C) cell 
proliferation was significantly inhibited by GW3965 treatment. At 72 hours, cell numbers were 
significantly lower in treated cells as compared to vehicle treated controls for all three cell lines. 
Titration curve experiments showed a dose-dependent inhibition of cell proliferation in all three 
cell lines. EC50 calculations indicated that BxPC-3 and MIA-PaCa-2 exhibited the greater 
GW3965 sensitivity (10.10 µM in BxPC-3 and 11.33 in MIA-PaCa-2), and PANC-1 cells were the 
least sensitive (13.66 µM). Additional studies using tetrazolium salt reduction assays further 
confirmed that GW3965 suppresses the growth of PDAC cell lines in a dose-dependent manner 
(Figure 2.2D). All three cell lines showed statistically significant drops in cell proliferation as 
measure by MTS reduction assays at 5 and 10 µM GW3965 for 72 hours as compared to vehicle-
treated controls(***P-Val < 0.001). Clonogenic assays were also employed to evaluate the effects 
of long-term LXR ligand treatment on cell proliferation and colony formation. Activation of LXR 
using GW3965 strongly inhibited colony formation in each cell line (Figure 2.2E-F). Inhibition was 
dramatic and statistically significant at 5 and 10 µM GW3965 (***P-Val < 0.001 in all three cell 
lines). Colony formation was inhibited by over 95% in all three PDAC cell lines when treated with 
10 µM GW3965 (Figure 2.2F). These findings suggest that LXRs are involved in PDAC cell 
proliferation and targeting LXRs with ligands perturb their normal functions in cell proliferation. To 
test this hypothesis and to determine the role of LXRs in mediating the effects of the ligands, we 
knocked down LXRα and LXRβ expression using small interfering RNAs (siRNAs). Transfection 
of PDAC cells reduced LXR expression 50-80% as compared to the controls (3.3A). Knockdown 
of LXRα had no effect on cell proliferation or response to treatment with the GW3965 ligand 
(Figure 2.3B). On the other hand, knockdown of LXRβ expression significantly reduced cell 
proliferation, even in vehicle treated cells, and ligand treatments following gene knockdown did 
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not further reduce cell proliferation. These results indicate that LXRβ is required for PDAC cell 
proliferation and response to LXR ligand treatment. 
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Figure 2.2. LXR agonists block cell proliferation and colony-formation in pancreatic cancer 
cells.  
(A), (B), (C), PDAC cells (BxPC-3, Mia-PaCa-2, and PANC-1 cell lines, respectively) show dose-
dependent decreases in cell proliferation upon treatment with increasing GW3965 concentrations. 
EC50 calculations indicate that BxPC-3 and Mia-PaCa-2 cells are more sensitive to ligand 
treatment than PANC-1 cells. D, Results from MTS assays, a separate measure of overall cell 
metabolic rate and indirect measurement of cell proliferation, demonstrate a dose-dependent 
drop in overall metabolism in cells treated with increasing concentrations of GW3965.  (E), 
Colony-formation ability in all three cell lines was blocked by GW3965 treatment.  (F), Colony 
formation of GW3965 treated cells was quantified relative to vehicle-treated controls. 
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Figure 2.3. Knockdown of LXRβ expression blocks PDAC cell proliferation and response 
to LXR ligand treatment.   
(A), Knockdown of LXRα and LXRβ expression was validated by quantitative PCR. Expression 
data were normalized to 36B4 ribosomal gene transcript levels. (B), The effect of LXR knockdown 
on PDAC cell proliferation was quantified by cell counts following trypan blue exclusion assays. 
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To examine whether the observed antiproliferative effects were due to the specific 
synthetic agonist used in previous studies, we treated PDAC cells alternatively with the T0901317 
ligand. Treatments with T0901317 blocked proliferation in two cell lines, BxPC-3 and Mia-PaCa-2, 
but not PANC-1 (Figure 2.4). T0901317 inhibited BxPC-3 and MIA-PaCa-2 proliferation by 40.2% 
and 54.2%, respectively, when compared to vehicle, and the differences are statistically 
significant (***p-val < 0.001). PANC-1 cell proliferation was inhibited 15.3%, but the effects were 
not statistically significant. To mitigate potential off-target effects posed by higher ligand doses, 
we treated PDAC cells at a titration of lower concentrations for longer time periods than those 
demonstrated in 3. 1 and Figure 2.2. Lower concentrations of drug were only slight in their effect, 
albeit reproducible. For 1 µM treatments of GW 3965, BxPC-3 proliferation was inhibited 10.2% 
(p-val = 0.01), MIA-PaCa-2 growth was inhibited by 11.2% (p-val = 0.02), and PANC-1 growth 
slowed by 16.9% (p-val < .001) (Figure 2.5A-C). Despite a response by PANC-1 at significantly 
lower concentrations of drug, there was never the precipitous drop observed in BxPC-3 and MIA-
PaCa-2 at higher concentrations, suggesting that PANC-1 is able to uncouple of the 
antiproliferative effect of GW 3965 over longer time periods. A similar long-term titration was 
performed using T0901317. The titration curves presented with a bimodal pattern suggesting off-
target effects depending on the concentration of ligand used (Figure 2.5D-F). Similarly to GW 
3965, T0901317 was maximally efficacious at 10 µM concentrations in all three cell lines. These 
findings suggest that there are ligand- and cell type-specific effects of LXR activation in PDAC 
cells.   
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Figure 2.4. Co-treatment of pancreatic cancer cells with LXR ligands and gemcitibine 
reveals additive antiproliferative effects.   
(A) Cell proliferation is blocked in BxPC-3, MIA-PaCa-2, and PANC-1 cell lines upon treatment 
with 10 µM GW 3965. (B) LXR agonist T0901317 blocks proliferation in BxPC-3 and MIA-PaCa-2 
cells, but is unable to block cell proliferation in PANC-1 cells. (C) GW3965 and gemcitibine block 
proliferation in all three pancreatic cancer cell lines and are additive in their inhibition of 
proliferation when administered concomitantly. 
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Figure 2.5. LXR ligands GW 3965 and T 0901317 have subtle effects on cell proliferation at 
lower concentrations and are concordant directionally with effects observed at higher 
concentrations.  
(A) BxPC3, (B) MIA-PaCa-2, and (C) PANC-1 titrations with varying concentrations of GW 3965.  
(D) BxPC3, (E) MIA-PaCa-2, and (F) PANC-1 cells treated with T 0901317. Cells were treated for 
1 week to more adequately resolve subtle differences in cell proliferation beween treatments. Cell 
proliferation is measured by MTS assay. 
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After demonstrating the antiproliferative effects of LXR ligands, we then compared their 
effects on PDAC cells to gemcitabine, a nucleoside analog chemotherapeutic with severe side 
effects. Cells were treated with vehicle, GW3965, gemcitabine (20 nM for BXPC-3, and 40 nM for 
MIA-PaCa-2 and PANC-1 cells), or combination of GW3965 and gemcitabine. Interestingly, 
GW3965 cooperated with gemcitabine to block proliferation in three pancreatic cancer cell lines to 
a greater extent than any treatment by itself. As expected, gemcitabine treatments inhibited 
proliferation in BxPC-3 by 49%, MIA-PaCa-2 by 77%, and PANC-1 cells by 71%; and the effects 
are significantly different when compared to vehicle (***p-val < 0.001) (3.4C). Co-administration of 
GW3965 and gemcitabine blocked proliferation in BxPC-3, MIA-PaCa-2, and PANC-1 cells by an 
additional 21.8%, 13.9%, and 10.5% respectively when compared to gemcitabine alone (*p-val < 
0.05 in BxPC-3 and PANC-1 cells, P-Val = 0.056 in MIA-PaCa-2 cells). A longer-term experiment 
(7 days) was performed to assess combinatorial effects of GW 3965 and a gemcitabine titration 
on cell proliferation, while determining the effect of a lower dose of GW 3965 on response to 
gemcitabine (Figure 2.6). These results demonstrate that gemcitabine is exceptionally 
antiproliferative, and that the additive effects of GW 3965 observed in Figure 2.4C are 
directionally consistent with Figure 2.6 and statistically distinguishable at lower concentrations of 
gemcitabine (1 nm), albeit insubstantial. These results suggest the possibility of future studies 
evaluating the effectiveness of GW3965 and gemcitabine as a combination therapy.  
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Figure 2.6. Gemcitabine titrations in PDAC cell lines are modulated by a low dose of GW 
3965.  
(A) BxPC3, (B) MIA-PaCa-2, and (C) PANC-1 cells treated with increasing concentrations of 
gemcitabine.  Subtle effects on gemcitabine response are only observed at very low 
concentrations of gemcitabine and are only statistically significant in BxPC-3 and PANC-1 cells. 
Cells were treated for 1 week to more adequately resolve subtle differences in cell proliferation 
beween treatments. Cell proliferation is measured by MTS assay.   
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2.3.3 Effects of LXR Ligand Treatment on Cell Cycle Progression 
 
Functional assays revealed that LXR ligand treatment blocked proliferation of PDAC 
cells. To better understand the mechanics of the antiproliferative effect, cell cycle analysis was 
performed following agonist treatment. Flow cytometry analysis revealed an additional 15.0% of 
BxPC-3 cells, 9.6% of MIA-PaCa-2 cells, and 8.4% of PANC-1 cells in G1/G0 phases of the cell 
cycle when treated with GW3965 (Figure 2.7A), and a corresponding 12.0% decrease of BxPC-3 
cells, 9.9% of MIA-PaCa-2 cells, and 9.0% of PANC-1 in cells in S/G2/M phases of the cell cycle 
(Figure 2.7B). These changes are statistically significant (P-Val < 0.001). Bromodeoxyuridine 
(BrdU) incorporation experiments showed a decrease in DNA synthesis by 12.9%, 27.0%, and 
21.0% in BxPC-3, MIA-PaCa-2, and PANC1 cells respectively (Figure 2.7C) (***p-val < 0.001). 
Representative histograms for BxPC-3 (Figure 2.7D), MIA-PaCa-2 (Figure 2.7E), PANC-1 (Figure 
2.7F) demonstrate a qualitative increase in G1 cells and a decrease in G2/M cells in GW 3965 
treated cells. Similarly, BrdU-incorporation density plots for each cell line demonstrate a 
qualitative decrease in BrdU+ cells upon treatment with GW 3965 (Figure 2.7G). Taken together, 
these findings demonstrate that LXR agonists inhibited PDAC cell proliferation by blocking cell 
cycle progression. To further uncover potential mechanisms of this effect on the cell cycle, we 
determined protein expression of cell cycle mediators known to be regulated by LXR ligand 
treatment in breast cancer cell lines[55]. Of the cell cycle regulators regulated in breast cancer 
cell lines, Skp2 is the only gene to respond in a similar manner between breast and pancreatic 
cancer cell lines. Western analysis confirms that Skp2, an oncogene, is downregulated 1.6 fold in 
BxPC-3 cells, 6.4 fold in MIA-PaCa-2 cells, and unchanged in PANC-1 cells when treated with 5 
µM GW 3965(Figure 2.8A-D) (*p-val < 0.05 in BxPC-3 and MIA-PaCa-2 cells, whereas p-val = 
0.43 in PANC-1 cells). A mechanism tying LXR directly to SKP2 transcriptional regulation, 
however, is not likely, as transcription levels do not correspond to protein levels upon treatment 
with GW3965 (Figure 2.9). This suggests that other, more upstream regulators are responsible 
for the observed antiproliferative effect. We specifically examined the expression of EGFR, a 
factor overexpressed in pancreatic cancers and the only non-chemotherapeutic marker that has 
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been successfully targeted in the treatment of PDAC [77]. EGFR is repressed 1.45 and 1.88 fold 
in the more sensitive BxPC-3 and MIA-PaCa-2 cell lines upon treatment with 5 µM GW3965 
(Figure 2.8B-C), and is statistically significant when compared to vehicle. This decrease in EGFR 
expression was not observed in PANC-1 cells, possibly due to their lesser sensitivity to LXR 
ligands (Fold Change: +1.24, p-val = 0.19) (Figure 2.8D). Decreases in EGFR expression levels 
in BxPc-3 and MIA-PaCa-2 coincide with decreases in phospho-EGFR (Tyr1173). Phospho-
EGFR levels decrease 1.93 fold in BxPC-3 and 1.65 fold in MIA-PaCa-2 (Figure 2.8A-C). To 
further assess the downstream effects of a downregulated EGFR in BxPC-3 and MIA-PaCa-2, 
ERK (p44/p42) and phosphorylation status were detected. No statistically significant changes to 
either total ERK or phospho-ERK were observed, suggesting that a downregulated EGFR could 
effect change on cell proliferation through other mechanisms. Taken together, these findings 
suggest that GW3965 inhibits transit of PDAC cells through the cell cycle, possibly by regulating 
key proteins that are responsible for G1-S transition and growth factor receptors that are heavily 
involved in regulating cell migration, proliferation, and survival [77,158].  
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Figure 2.7. LXR agonists block pancreatic cancer cell progression through the cell cycle. 
(A), GW3965 treatment arrests a significant proportion of the cells in the G1/G0 stage of the cell 
cycle as measured by propidium iodide staining and flow cytometry. (B), Fewer cells are found in 
S, G2, or M phases following ligand treatment. (C), BrdU-pulse analysis demonstrates that 
GW3965 treatments reduce transit through the S-phase of the cell cycle. (D), (E), (F) 
Representative cell cycle analysis diagram of BxPC-3, MIA-PaCa-2, and PANC-1 cells 
respectively. (G), (H), (I) Density plot depicting the number of cells staining for BrdU as a 
measure of S-phase transit in BxPC-3, MIA-PaCa-2, and PANC-1 cells. 
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Figure 2.8. GW 3965 down-regulates oncogenes involved in cancer progression.  
(A), GW3965 treatment downregulates Skp2 and EGFR protein levels in BxPC-3 and MIA-PaCa-
2 cells. Downregulation of EGFR was concomitant with a downregulation of its own 
phosphorylation in BxPC-3 and MIA-PaCa-2 at 5 uM GW 3965. ERK1/2 and its phosphorylation 
were not statistically different in any of the cell lines. (B), (C), (D) Densitometric quantification of 
SKP2, EGFR, Phospho-EGFR, ERK1/2, and Phospho-ERK1/2 upon treatment with GW3965. 
Samples were normalized to actin controls. 
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Figure 2.9. Validation of microarray on pancreatic cancer cell lines treated with LXR 
agonists reveal potential mechanisms of cell proliferation inhibition.  
(A) All cell lines share upregulated lipid biosynthetic regulators (Group 1). Type-I interferon 
mediated pathways are downregulated in three PDAC cell lines, but most robustly in BxPC-3 cells 
(Group 2). Genes that regulate apoptosis are downregulated strongly in BxPC-3 (Group 4). 
Mitotic cell cycle is downregulated most consistently in BxPC-3 cells, but also in MIA-PaCa-2 and 
PANC-1 cells (Group 5).   
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2.3.4 Microarray Analysis of Effects of LXR Ligands on Gene Expression 
 
Activation of LXR, a ligand-dependent transcription factor, is expected to directly or 
indirectly alter the expression of genes involved in proliferation-related pathways in pancreatic 
cancer cells. Microarray analysis of GW3965 responsive genes in three PDAC cell lines revealed 
common and cell line-specific responses. BxPC-3, MIA-PaCa-2, and PANC-1 cell lines showed 
distinct differences in the total number of up-regulated genes, numbering 2255, 865, and 676 in 
each respective cell line (Figure 2.10A).  Of these, only 85 had concordant responses in all three 
cell lines. A similar distribution of down-regulated responsive genes was noted in the three cell 
lines, with the most robust response observed in BXPC-3 cells, with 41 genes commonly down-
regulated in all three cell lines (Figure 2.10B). Gene ontology and pathway analysis of responsive 
genes showed that ligand treatment up-regulated genes involved in lipid metabolic, triglyceride 
biosynthetic, and long-chain fatty-acyl-CoA biosynthetic processes, including previously identified 
LXR target genes (Figure 2.10C). This is consistent with LXR’s known roles in cholesterol and 
lipid metabolism in other tissues [55]. Commonly down-regulated genes include those that 
regulate cellular response to viral infection (Figure 2.10C). Down-regulated pathways that were 
shared between BxPC-3 and PANC-1 cell lines regulate cell cycle progression and DNA 
replication, while down-regulated pathways shared between BxPC-3 and MIA-PaCa-2 regulate 
modulators of immune response, such as the innate immune response and type I interferon-
mediated pathways (Figure 2.9). Pathways responsible for cytoskeleton organization, apoptosis, 
and inflammatory-related pathways are also differentially expressed, which suggests that LXR 
ligands may regulate other cancer-related processes such as metastasis or cell survival in 
models of PDAC. These results indicate that activation of LXRs using LXR ligands result in 
dramatic antiproliferative and anticlonogenic effects in PDAC cells in general, but the underlying 
mechanisms of action appear to be varied.  
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Figure 2.10. Microarray analysis of pancreatic cancer cell lines treated with LXR ligands 
defines common and cell line-specific effects on gene networks.   
(A), (B), Venn diagrams of up-regulated and down-regulated genes (1.1 fold change cutoff) after 
treatment with GW 3965 for 72 hours. These cell lines show common and cell-line specific 
transcriptomic responses to ligand treatment.  (C),  Microarray analysis of upregulated genes 
show that all cell lines share up-regulation of lipid metabolic, glucose metabolic, and cell 
proliferation responses. All cell lines downregulate pathways that regulate response to viral 
infection, transmembrane support, as well as viral mRNA transcription. BxPC-3 and PANC-1 cells 
also downregulate cell cycle and DNA replication machinery. 
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Figure 2.11. LXR ligand treatment induces expression of known LXR target genes in PDAC 
cell lines.  
(A) ABCA1 is upregulated in all three cell lines by GW 3965 treatment, while SREBF1 is strongly 
upregulated in MIA-PaCa-2 and PANC-1 cells. ABCG1 is upregulated in MIA-PaCa-2 cells only. 
(P-Val * <0.05, **<0.025, ***<0.01). 
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2.4 Discussion 
In this study, we tested the hypothesis that LXR activation with synthetic agonists can 
halt the proliferation of pancreatic cancer cells. Before assessing the effects of LXR ligands in 
PDAC cells, we first demonstrated that LXRβ is the main LXR isoform detectable in human 
pancreatic ductal epithelial cells, as LXRα is not detectable in human normal pancreatic ducts 
(Figure 2.1E), pancreatic adenocarcinoma (Figure 2.1F), or in PDAC cell lines (Figure 2.1H). Our 
studies uncovered variation in the expression levels of LXRβ in PDAC cell lines, as well as 
differences in sub-cellular localization of LXRβ in PDAC primary samples (Figure 2.1A-D). 
Unliganded LXRβ has been shown to be partially exported from the nucleus to the cytoplasm 
[159], suggesting that there are either differences in endogenous activating ligands in clinical 
samples, or variable regulation of mechanisms involved in nuclear import/export where 
cytoplasmic staining of LXRβ is stronger (Figure 2.1B-C). Differential localization of LXRβ 
proteins in clinical samples suggests that LXRβ may be suppressed in malignant cells by 
exclusion from the nucleus, but a more comprehensive study is needed to determine whether 
cytoplasmic staining of LXRβ is associated with disease progression and patient survival.  
Functional assays clearly demonstrated that activation of LXRs by GW3965 in PDAC cell 
lines resulted in dramatic decreases in proliferation as measured by trypan blue exclusion assays 
(Figure 2.2A-C). Calculations of the EC50 for individual cell lines revealed that BxPC-3 and MIA-
PaCa-2 cells were more sensitive to ligand treatment than PANC-1 cells. This difference in 
response may be due to the lower expression of LXRβ in this cell line when compared to others 
(Figure 2.1E). PANC-1, therefore, may represent a more refractory cell line. This notion is further 
supported by clonogenic assays, which demonstrate reduced PANC-1 sensitivity to ligand 
treatment (Figure 2.2F), as well as complete PANC-1 insensitivity to another LXR agonist 
T0901317 (Figure 2.4B). T0901317 is a promiscuous binder of other nuclear receptors, such as 
farnesoid X and RAR-related receptors, which may explain why the effects of GW3965 (Figure 
2.4A) are not completely recapitulated by T0901317 [152,160-162]. The diverging effects of 
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alternative LXR ligands may also be attributable to differences in LXRβ expression levels, 
metabolism of the compound, or epigenetic modifications that potentiate alternative mechanisms.  
Recent advances in the treatment of PDAC pair the existing pair standard-of-care 
chemotherapeutic gemcitabine with an EGFR tyrosine kinase inhibitor such as erlotinib. Before 
this, gemcitibine was the first therapeutic that was able to extend survival since it replaced 5-
fluorouracil as the preferred chemotherapeutic agent in 1997 [163]. This suggests that 
combination therapy including gemcitabine is one of a limited set of viable strategies in the 
development of therapeutics for pancreatic cancer.  We demonstrate here that gemcitabine 
concomitant with GW3965 may be superior to either treatment by itself in the three pancreatic 
cancer cell lines (Figure 2.4C).  
To understand the cellular mechanisms underlying cancer cell proliferation inhibition by 
LXR agonists, we utilized flow cytometry to quantify changes in the cell cycle in PDAC cells.  
GW3965 treatment arrested PDAC cells in the G1/G0 phase of the cell cycle (Figure 2.7A,B). It 
also strongly inhibited BrdU incorporation, a measure of cell S-phase transition (Figure 2.7C). 
These data show that LXR activation by synthetic agonists results in cell cycle arrest, but does 
not indicate mechanisms linking LXR’s known role as a transcription factor to its antiproliferative 
effect. Here we show that Skp2, an oncogene previously shown to be down-regulated in ligand 
treated breast cancer cells, is down-regulated in two sensitive PDAC cell lines as a consequence 
of GW3965 treatment (Figure 2.8B-C). Skp2 is known to regulate c-Myc transactivation and 
ubiquitination, and regulates the turnover of other cell cycle regulatory units in maintenance of 
normal G1-S transition [161,162]. LXR ligand treatment also down-regulates epidermal growth 
factor receptor (EGFR) in two cell lines (Figure 2.7B-C), raising questions about LXRs and their 
effects on apoptosis and migration in PDAC, as EGFR is integrally linked to these pathways. 
Interestingly, activation of LXR using GW3965 has been shown to sensitize glioblastoma cells 
expressing EGFR splice variant (EGFRvIII) to apoptosis in in vivo models of glioblastoma [164]. 
We did not observe increases in cell death, however, following ligand treatment (Figure S5). 
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These results suggest that LXRs are integrally tied to machinery regulating cell cycle progression 
and growth factor signaling.  
It has been posited that gene networks involved in cholesterol and fatty-acid metabolism 
are tied to LXR’s emerging roles in cancer cell growth [55,165]. Activation of LXR leads to strong 
up-regulation of SREBF1 (sterol regulatory element-binding protein 1c) in breast, colon, 
pancreatic cancer cells (Figure 2.10C, 3.11), and is a regulator of lipogenesis and glucose 
metabolism [55,166]. Knockdown of SREBF1 protein in breast cancer cells, however, did not 
block cell proliferation inhibition by LXR agonists [55]. Interestingly, published studies linked sterol 
metabolic pathways to proliferation of T-cells through ABCG1 in normal T cell physiology. 
Inactivation of this transporter prevented LXRβ-mediated inhibition of proliferation in T cells [165]. 
The addition of low-density lipoproteins to the medium of T cells did not interfere with cell 
proliferation. These findings suggest that cholesterol may not only be a constituent of the cell 
membrane, but may be dynamically regulated intracellularly as a component of cell cycle 
progression controlled by cholesterol transporters and other factors.  Despite promising potential 
leads into mechanisms potentially regulated by LXR agonists, more work needs to be done in 
pancreatic tissues to elucidate how this effect is achieved.  
Mechanistically, our microarray study showed both concordant and discordant gene 
responses in three PDAC cell lines. Up-regulated genes (Figure 2.10A) are enriched for those 
known to function in cholesterol and fatty acid metabolism (Figure 2.10C), whereas down-
regulated genes (Figure 2.10B) were less concordant, and function in pathways that regulate 
response to viral infection (Figure 2.10C). Differences between cell lines in these responses can 
be attributed to variation in epigenetic modifications that potentiate LXR activity at response 
elements after ligand stimulation. Genome-wide microarray studies in breast cancer cells show 
that up-regulated genes tend to regulate cholesterol and fatty acid metabolism, whereas down-
regulated genes function in DNA replication and cell cycle programs. Specifically, treatments with 
LXR agonists down-regulated the expression of E2F2, a member of the E2F family of 
transcription factors. However, knockdown of E2F2 in breast cancer cell lines only blocked 
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proliferation in ER+ cell lines which suggests that mechanisms of cell proliferation inhibition by 
LXRs may be diverse in nature [56]. It is important to note that E2F2 is repressed significantly in 
BxPC-3 cells and not in the other two PDAC cells, and this observation suggests that 
mechanisms discovered in breast cancer cells may not necessarily be involved in pancreatic 
cancer cells. Differences in experimental design may also explain the variations noted between 
tissues (i.e. breast vs. pancreas). Treatment time was 72 hours for PDAC cell lines, whereas a 
shorter 48 hour-treatment was used for breast cell lines. Therefore, analyses in PDAC cells likely 
uncovered more secondary and tertiary responses to ligand treatment, and justifiably so because 
inhibition of cell proliferation by LXR is not thought to be a primary response. Future studies using 
shorter treatment times will shed light on early mechanisms underlying the effects of LXR 
agonists.  
These initial studies demonstrated the effects of LXR ligands on cell proliferation, but 
more work is needed to characterize their effects on other cancer-related processes.  Treatment 
with LXR agonists induced apoptosis in prostate cancer cell lines and xenograft models by down-
regulating AKT signaling [60]. However, our data show that LXR activation in pancreatic cancer 
cells was solely anti-proliferative, and lacked the ability to induce apoptosis as measured by 
caspase-3 cleavage (data not shown).  
Interestingly, LXRβ knockdown leads to a dramatic decrease in proliferation in PDAC cell 
lines (Figure 2.3B), which logically conflicts with the notion that LXRβ is antiproliferative. 
However, titration experiments using lower doses of GW 3965 to activate LXRβ have revealed a 
slight although reproducible effect on cell proliferation that is directionally consistent with higher 
doses (Figure 2.5). This suggests that the effect of GW 3965 is mediated through LXR, and the 
precipitous drop in proliferation observed at higher concentrations may be initiated by a cellular 
feedback or degradation mechanism, potentially altering both the available pool of RXR as well 
as available DNA binding sites in the absence of LXRβ. In spite of cursory evidence that GW 
3965 acts through LXR, there are possible antiproliferative effects that could be mediated through 
an LXR-independent mechanism.   
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Additional work is needed to characterize LXR function in the context of cell motility, 
migration, and the unique effects of other LXR ligands on pancreatic cancer biology in both cell-
based and animal models. These findings, however, indicate that LXR agonists and their 
derivatives warrant further study and development as potential therapeutic agents in the 
treatment of pancreatic cancer.  
 
2.5 Conclusions, Context, and Future Directions  
We demonstrate in these studies that LXR ligands result in dramatic antiproliferative and 
anticlonogenic effects in PDAC cells. LXRβ is the main isoform present in pancreatic ductal 
epithelial cells, and is abnormally localizated in PDAC patient tissues when compared to normal 
samples. Future experiments should analyze LXRβ expression levels in a larger cohort of 
cancers, which would allow for more quantifiable and statistical comparisons between cancerous 
and normal tissue. We show that LXRβ is required for PDAC cell proliferation and response to 
LXR ligand treatment. LXR ligand GW 3965 inhibits transit of PDAC cells through the cell cycle, 
possibly by regulating key proteins that are responsible for G1-S transition and growth factor 
receptors that are heavily involved in regulating cell migration, proliferation, and survival [77,158]. 
Future experiments should seek to better understand the mechanisms of LXR-mediated 
repression of EGFR, as a precise link has not been explored. This may allow for future 
combination therapies, as EGFR is a targeted marker in pancreatic cancer. Microarray studies on 
GW 3965 treated cells demonstrated a consistent effect of LXR ligands on fatty acid synthetic 
pathways, but less clear are the mechanisms of its effects of cell proliferation pathways. Future 
studies should utilize more comprehensive microarray experiments to look at the primary effects 
of the LXR ligands on gene transcription. We determined the effects of GW 3965 at 72 hours of 
treatment, which may be too long as these drugs are metabolized by enzymes and their 
responses uncoupled or attenuated. This would allow for the identification of key antiproliferative 
pathways targeted by the LXRs, and the development of more specific ligands to target them. 
Lastly, These ligands must also be tested in live animal models of pancreatic cancer. Preliminary 
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experiments are currently underway to test the viability of ligands as anti-cancer agents in 
immunocompromised mice. After this, the effect of LXR ligands on pancreatic cancer cell 
proliferation will be carried out on other mouse models with intact immune signaling because of 
the anti-inflammatory effects of the LXR ligands. Due to the limited nature of our understanding of 
the LXRs in cancer, more complete maps of the intersection between LXRs as metabolic 
regulators and the LXRs as antiproliferative agents are needed.   
The LXRs may be important for signaling the nutritional status within the organism. This 
may prevent the use of more advantageous energy sources by the cancer cells, and may 
represent one mechanism whereby LXR ligands suppress cell proliferation. Because the LXRs 
respond to cholesterol (derivatives), which are found in lipoprotein particles, it is possible that 
they are able to signal organismal-wide depletion of fatty acid stores in circulating 
lipoprotein particles. Uptake of these LDL particles in the liver results in the conversion of 
cholesterol into bile acids, and upregulates lipogenesis and circulating VLDL (increasing serum 
triglycerides). Interestingly, the receptor for LDL particles, LDLR, is downregulated by LXR 
ligands in glioblastoma cancer cells and HEPG2 cells [164,167]. VLDL, or lipoprotein particles 
that contain endogenously generated triglyceride particles, are recognized and imported by VLDL 
receptors in tissues throughout the body. Both LDLR and VLDLR both contain a recognition 
sequence of IDOL, or the inducible degrader of LDLR [167]. This degradation mechanism is 
activated by the LXRs to prevent further cholesterol import. As a consequence, activation of 
LDLR degradation with LXR ligands may also lead to the degradation of VLDLR, which would 
attenuate both the import of cholesterols and fatty acids into target tissues.  
It has been shown that the LXRs, FXR, and the PPARs are dynamically regulated to 
signal the nutritional status of the organism. A better understanding of the complex interplay 
between these receptors may facilitate more therapeutics that target the nutrient uptake and 
utilization of cancer cells. These receptors are integral to physiological decisions involved in 
energy allocation, such as activating or suppressing de novo lipogenesis in the liver, building up 
or breaking down glycogen stores, or burning/storing ingested fat compounds. For instance, 
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PPAR isoforms regulate the oxidation (α/δ) of fatty acids, whereas PPARγ regulates fat storage in 
adipose tissue [1]. The LXRs activate lipogenesis in the liver. It has also been shown that FXR 
activates VLDLR expression in human liver cells [168]. It is possible that LXR and FXR 
together are important for sensing the nutritional status of the organism. For instance, 
active FXR is indicative of reabsorbed bile acids in the portal vein. Signaling that a meal was 
ingested and is in the process of digestion and absorption. FXR may reactivate VLDLR 
suppressed by LXR-mediated degradation, which would further strengthen the notion of an LXR-
FXR relationship. Furthermore, FXRs are overexpressed in pancreatic cancers, which suggest 
that pancreatic cancers may respond more aggressively to FXR hormones circulating in the blood 
stream after their reabsorption in the intestine [169]. Therefore, it would be interesting to explore: 
1) the relationship between LXR agonists and LDLR/VLDLR expression levels in pancreatic 
cancers, and 2) the regulation of VLDLR levels response to FXR ligands in pancreatic cancers. A 
more complete understanding of the roles of these ligands in the regulation of cancer 
development and progression may lead to more targeted therapies with fewer side effects.  
Due to the roles of LXRs in regulating lipogenesis, there is the possibility that LXR 
ligands regulate cell division by modulating internal sensors of nutrient status. Cells that lack 
nutrients or growth factors innately activate autophagy pathways as a means to survive, which is 
a particularly complicated factor in cancers [170].  There is also the possibility that LXR ligands 
may regulate cancer autophagy and turnover of aging cellular products (due to the potential 
attenuation of VLDLR and LDLR or other LXR associated mechanisms). Autophagy is a complex 
process, and has roles in both protecting and preserving the cancer [171]. Preliminary 
experiments in our lab have shown an increase in the expression of autophagy markers in 
pancreatic cancer cells upon stimulation with LXR ligand GW 3965. Increases in autophagy may 
also explain decreased EGFR expression due to upregulated turnover and degradation of cellular 
products. Therefore, future projects will likely explore the relationships between fat 
(cholesterol/fatty acid) metabolic pathways and cell proliferation pathways, which will better 
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assess the viability of LXR ligands as cancer therapeutics in pancreatic cancer, and may provide 
more general mechanisms that may apply to other cancers and metabolic syndromes.   
In addition to their antiproliferative effects, the LXRs attenuate inflammation in mouse 
models.  Chronic and sporadic inflammation in the pancreas is a risk factor for the development 
of pancreatic cancer. These inflammatory events lead to the secretion of cytokines that are 
known to promote carcinogenesis, such as TGFβ, PDGF, and TNFα [172]. Inflamed tissues 
recruit immune mediators, which promote angiogenesis, extracellular matrix remodeling, and cell 
migration/metastasis. Concurrent with this is the recruitment of extensive stromal tissue around 
the tumor cells, which themselves secrete tumor promoting cytokines and growth factors to 
facilitate tumor growth and resistance to chemotherapeutics.  Constitutive expression of NFκB 
(the transcriptional effector of TNFα) has been observed in 67% of pancreatic cancers, which 
results in decreased apoptosis and an altered relationship with transrepressive nuclear receptors 
and mediators of the immune system [45,173]. NFκB is a transcription factor that controls genes 
responsible for proliferation, angiogenesis, motility, and invasiveness [174]. TNFα and NFκB 
factors also form an autoregulatory loop, which is thought to amplify inflammatory responses 
[172]. Therefore, NFκB is activated in most cancers and functions as an atypical oncogene. For 
these reasons, a more complete understanding of the general roles of LXRs in cancer-associated 
inflammation is needed.  
The best understood cell-based contribution of the immune system to an aggressive 
cancer outcome, however, is signaling that regulates macrophage phenotypes, which are 
classified as type M1 or M2 [174,175]. The M1 macrophage program is activated by IFN-γ and 
components of pathogenic machinery, and express inflammatory cytokines such as TNF-α, IL-6, 
IL-23, and IL-1. Conversely, M2 macrophage (very similar to tumor associated macrophages) 
programs are typically activated once the pathogen has been eliminated and are induced by IL-
10, an anti-inflammatory cytokine, and mediate healing of tissue damaged by pathogens and 
aggressive M1 macrophage activities [174,176]. Future experiments should determine more 
precisely how the stimulation of the LXRs with ligands effects, 1) NFκB activity and inflammatory 
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signaling in the main tumor cells, 2) the transcriptome and phenotypes of macrophages 
embedded in the tumor microenvironment, and 3) regulation of the tumor associated stroma by 
LXR ligands. These experiments will require the use of special mouse models of pancreatic 
cancer where the immune signaling is intact. Syngenic tumor models or mice genetic lines that 
spontaneously generate pancreatic tumors are possible future directions for these sorts of 
experiments.  KPC mice, however, conditionally express mutant p53 and Kras in pancreatic cells 
(Pdx1-Cre) and develop pancreatic adenocarcinomas that recapitulate traits of human pancreatic 
adenocarcinomas, which tend to be poorly vascularized and insensitive to gemcitabine [177]. 
Poor vascularization is not recapitulated by other xenograft or cell line models of pancreatic 
adenocarcinoma. Therefore, the KPC mouse would be the optimal model to study the immune 
component of pancreatic cancer. These data will hopefully yield a better understanding of the 
mechanisms of LXRs in pancreatic cancer in these diverse contexts, including nutrient absorption 
and utilization, growth factor signaling, autophagy, and the interaction with immune and 
inflammatory components of the cancer stroma.  
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3. Alcohol Regulates Genes that are Associated with 
Response to Endocrine Therapy and Attenuates the 
Actions of Tamoxifen in Breast Cancer Cells 
 
3.1 Introduction 
More than 230,000 women will develop breast cancer in the US this year, which is currently one 
of the most common causes of cancer deaths in American women and is the most costly of all 
cancers (Cancer Facts and Figures, American Cancer Society, 2014). A more complete 
understanding of genetic, hormonal, environmental, or behavioral factors involved in the 
development of breast cancer may provide more effective preventative measures as well as more 
targeted therapeutics.  Many contributing factors are known to increase breast cancer risk, 
including modifiable behaviors such as alcohol consumption. Epidemiological studies have 
strongly linked alcohol consumption to increased breast cancer risk [147-150]. Moreover, these 
studies also show that breast cancer risk is positively correlated with the amount of alcohol 
consumed. Alcohol consumption also positively correlates with increases in breast area covered 
by dense parenchymal tissue and decreased β-carotene circulation, parameters which are 
individually known to result in increased breast cancer risk [178-181]. Furthermore, some gene 
product mutations (such as GSTM1) potentiate the risk for alcohol-associated cancers [182]. 
Given how extensive alcohol consumption is among women in the United States, and the 
presence of other significant public health challenges related to alcohol abuse, alcohol 
consumption is a key modifiable factor in the development of breast cancer.  
 Alcohol-associated breast cancers tend to be estrogen receptor (ER)-positive and 
progesterone receptor (PR)-positive [178,183-186]. Studies examining the potential effects of 
alcohol consumption on the amount of circulating estrogens in the body have failed to identify a 
consistent correlation, suggesting that alcohol likely mediates more direct effects on signaling 
mechanisms in the breast to promote carcinogenesis [187,188]. It has been shown that alcohol 
stimulates proliferation, up-regulates ERα and aromatase expression, and attenuates BRCA1 
expression in ER+ cell lines [189,190]. Furthermore, it has been previously shown that alcohol 
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up-regulates polymerase III specific genes, and that this effect is countered by treatment with ER 
antagonists [191,192]. Alcohol has also been shown to increase the migration and invasion of 
breast cancer cell lines, which could be mediated through decreased E-cadherin expression, or 
up-regulated matrix metalloproteinase secretion [193,194]. Conversely, alcohol has been shown 
to suppress lung metastasis of 4T1.2 breast cancer cells, which are ER- [195]. These results are 
difficult to interpret due to the tendency of alcohol-associated cancers to be ER+/PR+. However, 
another study shows that alcohol increases lung metastasis of an ER+ cell line, MADB106 [196]. 
These experiments were performed in male rats, but demonstrate that alcohol may regulate 
breast carcinogenesis in an estrogen-dependent manner. Taken together, these observations 
suggest that the effects of alcohol are dependent on the ER machinery. ER and PR are markers 
of estrogen-dependent tumor growth and sensitivity to endocrine therapy with selective estrogen 
receptor modulators (SERMs), which block ER activity in the breast, or aromatase inhibitors, 
compounds that attenuate de novo estrogen production in breast tissue [197]. Patients, especially 
postmenopausal women, who are taking SERMs while consuming alcohol are at a higher risk of 
recurrence [198]. The full extent of the impact of alcohol on ER-regulated and ER-independent 
mechanisms remains to be determined, including interactions between alcohol, estrogen, and 
SERMs used to treat hormone-dependent breast cancers. In this study, we investigated the 
effects of alcohol on growth factor and estrogen signaling, gene regulatory networks involved in 
clinical outcomes in breast cancer patients, the effects of alcohol on tamoxifen response in ER+ 
cell lines, as well as the functions of alcohol-regulated genes in breast cancer cell proliferation.  
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3.2 Materials and Methods 
3.2.1 Cell Culture 
Three standard human breast cancer cell lines were selected for use in these studies: MCF-7, 
T47D, and MDA-MB-231, (American Type Culture Collection, Rockville, MD, USA). MCF-7 cells 
were grown in high glucose Dulbecco’s modified Eagle’s medium buffered in HEPES (Invitrogen, 
Carlsbad, CA, USA). The media were supplemented with 10% fetal bovine serum (Hyclone, 
Logan, UT, USA).  T47D and MDA-MB-231 cells were grown in DMEM/F12 (Invitrogen) 
containing HEPES and glutamine. These cells were further supplemented with 10% FBS 
(Hyclone). Cells requiring estrogen-depeletion were washed in PBS and grown in DMEM or 
DMEM/F12 lacking phenol and supplemented with 10% charcoal/dextran filtered fetal bovine 
serum (Hyclone).  
 
3.2.2 Cell Proliferation Assays, Cell Treatments, and Gene Knockdowns 
Cells were treated with 10 nm 17β-estradiol (Sigma-Aldrich, St. Louis, MO, USA), 500 nm 4-
hydroxytamoxifen (Tocris Bioscience, Bristol, UK), ethanol, or with DMSO as a vehicle. Cell 
proliferation was measured in one of two ways. Trypan blue exclusion assays were used to 
manually count cells using a hemocytometer. Otherwise, cell proliferation was measured using a 
standard MTS reagent, CellTiter96 Aqueous One Solution (Promega, Madison, WI, USA), 
according to the manufacture’s standard protocol. For combination experiments in Figure 3.3, 
7500 MCF-7 or T47D cells were seeded in a 96-well format, whereas 5000 MDA-MB-231 cells 
were similarly seeded for experimentation. Statistical analysis of these experiments was carried 
out using a standard two-tailed Student’s t-test. All experiments were performed in triplicate. 
BRAF knockdown was accomplished by transfecting breast cancer cell lines with one of two 
targeting siRNAs following the standard manufacturer’s protocol (Thermo Scientific Dharmacon, 
Lafayette, CO, USA). Scrambled siRNA from the same manufacturer were utilized as negative 
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controls. In these experiments, 5000 MCF-7 cells were seeded into a 96-well format for 
knockdown and subsequent MTS assays.  
 
3.2.3 Western Blotting 
Cells were starved of estrogen for 72 hours prior to indicated treatment conditions for 24 hours. 
Cells were then lysed in standard RIPA lysis buffer. Protein concentrations were determined with 
Qubit Protein Assay Kit (Invitrogen). 100 µg of protein was loaded into 10% polyacrylamide gels. 
After separation, the proteins were then applied to PVDF transfer membranes (Thermo Fisher 
Scientific, Rockford, IL, USA). After transfer, the membranes were blocked in TBST with 10% 
dissolved nonfat milk. After blocking, the membrane was probed with antibodies directed against 
pERK1/2 (Cell Signaling, Danver, MA, USA), ERK1/2 (Cell Signaling), BRAF (Santa Cruz), or 
GAPDH dissolved in 1% milk/TBST for 4 hrs to overnight. Membranes were washed of unbound 
or non-specific antibody and reprobed with horseradish peroxidase (HRP) specific secondary 
antibodies for 1 hr. Following a second wash, the film was exposed to ECL reagent (Thermo 
Fisher Scientific), to allow for their detection by blue autoradiographic film. Fold change 
quantification in protein levels was analyzed using the densitometric analysis package in ImageJ 
software (version 10.2) [199].  
 
3.2.4 Illumina Bead Chip Arrays and Data Analysis 
Total RNA from MC7-7 cells was isolated with RNeasy columns (Qiagen). 250 ng of RNA was 
converted to cRNA using the Illumina TotalPrep-96 RNA Amplification kit (Ambion, Carlsbad, 
CA,USA). Next, cRNA from the amplification kit was hybridized to the Illumina Whole-Genome 
Gene Expression Direct Hybridization Microarray (Illumina, San Diego, CA, USA). Duplicate 
probes were eliminated. R software packages lumi and limma were then used to identify 
differentially expressed genes in alcohol-treated MCF-7 cells. Overall intensity values obtained 
from this analysis were normalized. P values were then adjusted with the Benjamini-Hochberg 
correction used to account for false discovery in genome-wide analyses. Fold change values in 
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excess of 1.1 were then used to populate a list of responsive genes for data mining. Bioinformatic 
analysis of responsive genes was made in Pathway Studio (Ariadne Genomics, Rockville, MD). 
Fisher’s exact test was used to determine statistically enriched pathways. The microarray data 
have been uploaded to the Gene Expression Omnibus repository and will be available to the 
public following publication (GSE66406).  
 
3.2.5 Survival Analysis 
Clinical microarray gene expression data generated from a cohort of breast cancer patients in 
Uppsala, Sweden were used to correlate responsive alcohol genes with disease parameters and 
outcomes [104]. Dendrograms were generated with Eisen Cluster and Treeview software. 
Survival analyses were generated using the survival plot functions (log-rank test) of Mathematica 
software. No consent or institutional review is required for this data as the analyses were based 
on previously published and publically available data.  
 
3.2.6 Quantitative PCR 
 
RNA from treated cells was extracted using the RNeasy Kit (Qiagen). Then, 0.5 µg of RNA was 
reverse transcribed using SuperScript III Reverse Transcriptase System (Invitrogen). Quantitative 
PCR was done on a 7500 Fast Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) 
using Fast SYBR Green Master Mix (Applied Biosystems). Primer BLAST was then used to 
generate primers specific for these genes listed in Table 3.1. The ΔΔCt method was used to 
calculate fold changes between treatment conditions by normalizing to 36B4, a housekeeping 
gene (36B4 forward 5’-GTGTTCGACAATGGCAGCAT-3’; 36B4 reverse, 5’-
GACACCCTCCAGGAAGCGA-3’). 
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Table 3.1 Primers Used in Chapter 3 
Gene Forward Primer Reverse Primer 
H19 5’-AGCCTCCACGACTCTGTTTC-3’ 5’-TCCACAACTCCAACCAGTGC-3’ 
PPARg 5’-ATGAGTCTTCACCCGCTCCT-3’ 5’-GGAAATGTTGGCAGTGGCTC-3’ 
WISP2 5’-CTGGGCTGATGGAAGATGGT-3’ 5’-AGTGAGTTAGAGGAAAGGGGAC-3’ 
DHRS2 5’-GCAGAGGATTGGGGAGTCAG-3’ 5’-TCAGAGCCGAGTGGAGTAGC-3’ 
SKP2 5’-CCCAGGAACTGCTCTCAAA-3’ 5’-CTGCGGACAATCACAAAGT-3’ 
DHRS3 5’-AGCCACCTTGACACTTTTGAAC-3’ 5’-TGGGTTTTGGAACGGGAGG-3’ 
BRAF 5’-TCTCACCAGTCCGTCTCCTT-3’ 5’-TCCTCCATCACCACGAAATCC-3’ 
STIL 5’-CCAGCCACTTTCTGTATCC-3’ 5’-GCACCCCCTGTTGGTC-3’ 
CYP26A1 5’-CCAGAAAGTGCGAGAAGAGC-3’ 5’-TTCAGAGCAACCCGAAACCC-3’ 
TGFBI 5’-CCCTGAGAGACCTGCTGAAC-3’ 5’-CGCCTTCCCGTTGATAGTGA-3’ 
ALDH1A3 5’-AGCAGCCGTGTTCACAAAAA-3’ 5’-GTAGCAGTTGATCCAGACCGT-3’ 
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3.3 Results 
3.3.1 Ethanol Promotes Estrogen and Growth Factor Signaling Mechanisms in Breast 
Cancer Cell Lines. 
 
To optimize the study of the effects of alcohol on breast cancer cell proliferation, several 
parameters were first established. MCF-7 breast cancer cells were primarily used in these studies 
because they are derived from the breast tumor subtype most commonly associated with alcohol 
consumption (ER+/PR+). They are also the most frequently used ER+ cell line and the most 
comprehensively studied. Cells were starved of estrogen (E2) in phenol-free medium 
supplemented with 10% charcoal filtered FBS for 72 hours prior to the specified treatments. 
Drugs and hormone compounds were dissolved in DMSO instead of ethanol to independently 
assess the effects of alcohol on breast cancer cell biology. After starvation and treatment, we 
performed trypan blue exclusion assays to evaluate whether alcohol is sufficient to drive ER+ 
breast cancer cell line proliferation in the absence of estrogen, which is a major target in these 
types of breast cancer. These results show that alcohol increased cell proliferation in MCF-7 cells 
only in the presence of estrogen (5.1A). Cells treated with ethanol in the absence of E2 did not 
proliferate more than cells treated without ethanol (p = .77, FC = 0.97). As a positive control, E2 
significantly increased proliferation in ER+ MCF-7 cells over untreated cells (p < 0.001). Alcohol 
further promoted a 21% increase in cell proliferation in E2 treated cells (p = 0.006), demonstrating 
that conditions used in these studies were sufficient to evaluate breast cancer responses to 
alcohol. To establish the optimal working concentration of alcohol for use in functional studies, we 
performed a titration of alcohol concentrations in MCF-7 cells grown in cell medium containing 
estrogen, then subjected them to tetrazolium salt reduction assays (MTS), which measure 
mitochondrial metabolic rate and act secondarily as higher throughput reflections of cell number. 
In this assay, cells proliferated 24% more in response to 43.4 mmol/L ethanol and elicited the 
most potent response (Figure 3.1B) (p < 0.001 for 21.7, 43.4, and 65.1 mM ethanol treatments). 
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Cells treated to 86.8 mM ethanol were not statistically different from untreated cells, suggesting a 
suppressive effect on cell proliferation at this concentration. Furthermore, 43.4 mM  ethanol was 
slightly more potent than 21.7 mM ethanol at increasing estrogen-dependent cell proliferation. 
This concentration was used for the remaining cell proliferation experiments. A blood alcohol 
content as low as 17.4 mM (~0.08%) begins to impair normal behaviors, and is considered a 
binge drinking episode [200]. Furthermore, the alcohol concentrations used in the cell proliferation 
experiments are higher than the amount attained in average binge episodes, but are lower than 
the achievable blood alcohol concentrations observed in alcohol patients [201].  
Critical signals for estrogen-dependent cell proliferation are ERK1/2 phosphorylation, 
which is mediated though increased ER target gene transcription in response to estrogen, 
resulting in amplified HRG/HER2 signaling, and therefore increased growth [202]. To test whether 
alcohol modulates these signaling mechanisms, we carried out western blot experiments on 
combination estrogen and alcohol treated MCF-7 cells. These experiments showed that alcohol 
increased ERK1/2 phosphorylation (Figure 3.1C). Furthermore, pERK was increased 1.49 fold (p 
= 0.01), whereas the pERK of E2 treated cells was increased 2.3 fold (p = 0.001). Combination 
E2 and ethanol treatments increased pERK phosphorylation 2.8 fold relative to DMSO (p = 
0.001). Alcohol promoted ERK phosphorylation in MCF-7 cells independent of estrogen 
treatment, but is still required for increased cell proliferation, suggesting estrogen-dependent and 
–independent mechanisms of alcohol activity in breast cancer cell lines. Despite an effect by 
alcohol on ERK phosphorylation levels, these experimental results demonstrated that alcohol is 
not sufficient to promote cell proliferation in the absence of estrogen.  
Our interests in the effects of alcohol on estrogen signaling are based partially on 
previously published studies, which have shown that alcohol regulates estrogen receptor 
expression and transcriptional activity [189,203]. To confirm these results, MCF-7 cells were 
treated with alcohol and/or E2 and subjected to gene expression analysis. TFF1/pS2 and GREB1 
are two well-known estrogen responsive genes (Figure 3.1D). GREB1 expression was amplified 
15.09 fold in E2 and ethanol treated cells over DMSO. However, GREB1 was upregulated 11.46 
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fold in cells treated with E2 alone. This difference was statistically significant (p = 0.05). 
Expression levels of the TFF1/pS2 mRNA transcript, however, was not statistically different 
between E2 and E2/EtOH treated samples, suggesting that alcohol does not amplify the 
expression of estrogen responsive genes in a universal fashion. 
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Figure 3.1. Alcohol increases cell proliferation in an estrogen-dependent manner, 
promotes the activation of ERK1/2, as well as known ER target genes.  
(A), Trypan blue exclusion assays demonstrate that estrogen potentiates cell proliferation 
increases by alcohol. DMSO treated cells are not statistically different from DMSO and alcohol 
cotreatment. (B), MTS assays measure statistically significant increases in metabolic rate at 21.7, 
43.4 and 65.1 mmol/L ethanol concentrations. Treatment with 86.8 mmol/L EtOH did not result in 
an increase in cell proliferation. (C) Alcohol promotes the phosphorylation of ERK1/2, a key 
effector of growth factor signaling and of G1-S progression, regardless of estrogen treatment. 
Quantification comprises data of experiments in triplicate. (D) The effect of alcohol was tested on 
ER responsive genes TFF1/pS2 and GREB1 in MCF-7 cells. Only GREB1 responds to alcohol 
treatment, suggesting a possible overlap between cellular estrogen signaling and alcohol 
response. 
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3.3.2 Alcohol Treatment Regulates Genes Involved in Key Cellular Processes that are 
Associated with Patient Survival and Response to Endocrine Therapy. 
 
To better characterize potential mechanisms of alcohol action in breast cancer cells, ethanol-
treated MCF-7 cells starved of estrogen were subjected to a genome-wide microarray analysis. 
Differentially expressed genes were defined by fold change cutoffs and false discovery corrected 
p-values.  Overall, 898 genes were upregulated, and 654 genes were down-regulated by ethanol 
(Figure 3.2A). A small portion of these genes overlapped with known ER target genes [127]. 
Genes that were regulated by alcohol treatment independent of a known ER-binding site are 
termed “alcohol specific genes” in this analysis. 77 up-regulated ethanol responsive genes 
overlapped with the 904 previously identified ER target genes, whereas 37 down-regulated 
ethanol responsive genes overlapped with known ER target genes (Figure 3.2A). Gene ontology 
analysis showed that alcohol responsive genes regulated a wide variety of molecular pathways. 
Up-regulated alcohol-specific genes governed cell cycle and apoptotic genes. Furthermore, the 
down-regulated alcohol-specific genes are also involved in apoptosis, vesicle-mediated transport, 
and response to oxidative stress (Table 3.2). The limited number of genes that overlapped with 
estrogen signaling (ER target genes) were involved in cell migration, cell adhesion, and skin 
development (Table 3.3). Such a limited number of known estrogen responsive genes regulated 
by alcohol treatment suggested that alcohol was unlikely to independently regulate estrogen 
signaling or cell proliferation through ER. However, these results provide early leads into potential 
ER-independent mechanisms that are regulated by alcohol. 
 
 
 
 
70 
 
Figure 3.2. Gene networks regulated by alcohol treatment in MCF-7 cells are strongly 
correlated with breast cancer disease parameters. 
(A) Representative Venn diagram demonstrating the number of up-regulated and down-regulated 
genes, as well as the overlap of ethanol responsive genes with ER target genes.  (B) Up-
regulated and (C) down-regulated alcohol responsive genes were analyzed for expression in a 
patient microarray (Upsalla database). Patients were then clustered into two groups based on 
their gene expression profiles. Parameters were correlated for DFS (disease-free survival), DMFS 
(mestastasis-free survival), and DSS (disease-specific survival). Survival plots of subdivided 
patient groups show that both up-regulated and down-regulated alcohol responsive genes are 
associated with clinical parameters and disease progression. (Patient dendrograms correspond to 
survival plots based on color). 
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Table 3.2. GO categories enriched in alcohol-specific 
responsive genes. 
GO Category Study/Category 
Up-regulated Genes 
 cell cycle 54/604 
apoptosis 62/778 
chromatin modification 32/262 
protein ubiquitination 27/220 
protein transport 49/602 
protein phosphorylation 55/743 
cell proliferation 38/429 
interspecies interaction between 
organisms 32/325 
RNA splicing 31/323 
protein dephosphorylation 21/166 
response to DNA damage stimulus 30/309 
Down-regulated Genes  oxidation-reduction process 59/840 
transcription, DNA-dependent 113/2265 
apoptosis 51/778 
response to oxidative stress 19/150 
multicellular organismal development 66/1146 
vesicle-mediated transport 24/244 
tRNA processing 14/89 
viral reproduction 30/362 
carbohydrate metabolic process 30/369 
regulation of apoptosis 24/263 
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Table 3.3. GO categories enriched in alcohol-responsive ER target genes. 
GO Category Study/Category 
Up-regulated Genes  
skin development 4/54 
axon guidance 6/328 
epithelial cell maturation 2/9 
cell migration 4/141 
response to chemical stimulus 3/65 
mRNA polyadenylation 2/18 
ectoderm development 2/20 
transport 11/1812 
epithelial cell maturation in salivary gland development 1/1 
epithelial cell fate commitment 1/1 
serotonin secretion, neurotransmission 1/1 
Down-regulated Genes  
regulation of cell shape 2/76 
lipopolysaccharide transport 1/2 
detection of lipopolysaccharide 1/3 
negative regulation of microtubule polymerization 1/4 
recognition of apoptotic cell 1/4 
cell adhesion 3/686 
tyrosine catabolic process 1/5 
cholesterol import 1/5 
regulation of phagocytosis 1/6 
positive regulation of cholesterol storage 1/6 
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To determine the potential clinical significance of alcohol responsive genes in breast 
cancer patients, we examined their expression profiles of alcohol responsive genes in a 
microarray dataset of breast cancers. This dataset contains expression data from a cohort of 
patients with corresponding morbidity and mortality data. Only patients with ER+ breast cancers 
being managed by endocrine therapy were included in this analysis, due to the clinical and 
pathological parameters that are associated with alcohol consumption. Hierarchical clustering of 
these patients was performed based on the expression profiles of alcohol up-regulated and down-
regulated genes. Patients were then placed into one of two patient groups based on the 
hierarchical clustering patterns. The two groups were subsequently analyzed for disease-free 
survival (recurrence; DFS), distant metastasis-free survival (metastasis; DMFS), and disease 
specific survival outcomes (death; DSS). The up-regulated gene subset was associated with 
recurrence (p < 0.05) and death (p < 0.01) (Figure 3.2B), whereas the down-regulated subset 
clustered patients groups with very different recurrence, metastasis, and death outcomes (p < 
0.01, 0.025, and 0.001 respectively) (Figure 3.2C). Based on these survival analyses, it appears 
that alcohol responsive genes may serve as prognostic markers for patient response to endocrine 
therapy.  
 
3.3.3 Alcohol Blocks Tamoxifen in ER+ Breast Cancer Cell Lines. 
 
 
Due to the potential association of alcohol with response to endocrine therapy, we tested the 
hypothesis that alcohol may directly antagonize tamoxifen activity in breast cancer cells. In these 
experiments, we utilized MTS assays to measure metabolic rate in two standard ER+ cell lines 
(MCF-7 and T47D) and one ER- negative cell line (MDA-MB-231). As expected, the ER+ cell 
lines proliferated in response to E2 (80% in MCF-7 cells and 32% in T47D cells when compared 
to vehicle; p < 0.001 in both MCF-7 and T47D cells, Figure 3.3A-B). Furthermore, alcohol 
increased proliferation an additional 38% in MCF-7 cells and 23% in T47D cells over E2 alone (p 
≤ 0.001 in both cell lines). As a control, tamoxifen treatment suppressed E2 induction of cell 
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proliferation in both ER+ cell lines. To determine the association between alcohol and response 
to tamoxifen, ethanol co-treatment with E2 and tamoxifen increased cell proliferation 24.8% and 
13.8% in MCF-7 and T47D cells respectively over E2 and tamoxifen treated cells (p < 0.01 in 
both cell lines). MDA-MB-231 cells did not respond to alcohol or ER ligands (Figure 3.3C). These 
data provide a direct link between alcohol responsive genes and previously published 
epidemiological data, in that expanded cell proliferation provided by estrogen and other factors is 
often a risk factor for the development of breast cancer [204]. These data also provide the 
mechanistic basis for the association between alcohol responsive genes and patient response to 
endocrine therapy.  
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Figure 3.3. Alcohol enhances estrogen-dependent increases in cell proliferation and 
blocks tamoxifen attenuation of cell proliferation in MCF-7 and T47D cells.  
(A), MTS assays demonstrate that alcohol is able to increase measures of metabolic rate in 
estrogen-treated MCF7 cells. Alcohol also largely blocks a dose of tamoxifen after 72 hours of 
treatment, suggesting a role for alcohol in breast cancer insensitivity to SERMS. (B) Similar 
results were observed in another ER+ cell line, T47D. (C) MDA-MB-231 cells do not respond to 
estrogen, tamoxifen, or ethanol. 
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3.3.4 BRAF is a Novel Ethanol Responsive Gene that Promotes Breast Cancer Cell 
Proliferation. 
 
 
Previous analyses of ethanol responsive genes demonstrated a strong link between alcohol-
responsive genes and clinical outcomes, but involved the clustering of patients based on a large 
number of alcohol-responsive genes (Figure 3.2). To ascertain the contributions of individual 
alcohol responsive genes to the phenotypes observed earlier, alcohol-responsive genes were 
analyzed for their differential expression based on clinical outcomes in ER+ breast cancers 
treated with endocrine therapy. Single genes with statistically significant differing expression 
levels were identified in patients who experienced recurrence (DFS), metastasis (DMFS), or 
death (DSS) (Table 3.4). Several, alcohol-responsive genes were identified in the microarray 
analysis and are involved in regulating cell proliferation (BRAF, SKP2, PPARG). These and other 
genes involved in the metabolism of alcohol were validated by qPCR (Figure 3.4A). The top 
responsive gene, BRAF, a downstream effector of growth factor signaling and a proto-oncogene, 
was induced 2.00 fold over untreated cells (p < 0.05) at the transcript level (Figure 3.4A). Ethanol 
promoted a 3.15 fold increase in BRAF protein levels in MCF-7 cells (p = 0.008). Treatment with 
E2 increases BRAF levels 3.15 fold (p = 0.001), whereas E2 and EtOH treatment increased 
BRAF levels 4.26 fold (p = .004). BRAF levels for MCF-7 cells treated with E2 and alcohol were 
not always increased over E2 treatment alone, but a distinct trend was present (p = 0.18) (Figure 
3.4B). Taken together, these data show that BRAF is a novel alcohol and estrogen responsive 
gene, which is overexpressed in breast cancer patients with poorer DSS parameters.  
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Table 3.4. Alcohol-responsive genes differentially 
expressed between outcome groups. 
Gene DFS DMFS DSS 
Up-regulated Genes    
STIL 0.002 0.004 0.001 
ASCL1 0.019 0.035 0.003 
TULP4 0.244 0.008 0.005 
RIF1 0.294 0.02 0.005 
MIER3 0.002 0.007 0.007 
BRAF 0.176 0.054 0.014 
ID2 0.225 0.263 0.016 
SKP2 0.505 0.081 0.022 
TP53INP1 0.081 0.059 0.022 
PHIP 0.594 0.65 0.049 
Down-regulated Genes   
WISP2 0.001 0.001 0.001 
DIO2 0.013 0.007 0.002 
H19 0.005 0.005 0.011 
PPARG 0.132 0.048 0.014 
VEGFB 0.012 0.023 0.020 
RBPMS 0.121 0.141 0.025 
DICER1 0.008 0.008 0.026 
DHRS2 0.676 0.633 0.039 
ITGB5 0.002 0.01 0.048 
VGF 0.005 0.014 0.048 
DFS: Disease-free Survial (Recurrence) 
	  DMFS: Distant Metastasis-free Survial (Metastasis) 
	  DSS: Disease-specific Survial (Death) 
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Due to its known roles in cell proliferation and oncogenesis, we examined the effect of 
BRAF on alcohol response in MCF-7 cells. First, BRAF siRNA knock-down suppressed BRAF 
transcript and protein levels (Figure 3.4C). We then performed knock-downs of BRAF and 
determined their effects on cell proliferation using MTS assays. Knock-down of BRAF attenuated 
basal proliferation rates, as well as estrogen-dependent proliferation in MCF-7 cells. Furthermore, 
knock-down of BRAF was able to partially attenuate alcohol response, especially with construct 2 
(Figure 3.4C). Furthermore, BRAF regulated basal, as well as estrogen-dependent proliferation in 
MCF-7 cells. Lastly, Kaplan-Meier survival analysis of patients based on BRAF expression levels 
showed statistically significant DMFS and DSS outcomes in ER+ breast cancer patients (p = .02 
and 0.03, respectively), where women with higher expression of the BRAF mRNA responded 
more poorly to endocrine therapy (Figure 3.5). These results identified BRAF as a novel alcohol 
responsive gene, whose expression is correlated with disease outcomes, and is involved in 
breast cancer cell proliferation.  
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Figure 3.4. Alcohol regulates BRAF, an effector of growth factor signaling, and promotes 
estrogen-dependent and –independent growth.  
(A), Microarray validation demonstrates subtle but highly reproducible effects on gene expression 
of down-regulated and up-regulated genes. (B) BRAF is up-regulated at the protein level by 
alcohol and estrogen treatment. (C) BRAF is targetable with siRNA knockdown for functional 
studies. MTS assays demonstrate the anti-proliferative effect of BRAF knockdown on MCF-7 
cells, suggesting that BRAF promotes basal cell proliferation in the absence of estradiol, 
increases estrogen-dependent growth, and potentiates some of the cell’s response to ethanol. 
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Figure 3.5. High BRAF expression levels correlated ER+ endocrine treated patients with 
poor prognosis and response to therapy.  
(A) BRAF is expressed at higher levels in patients who experience metastasis or do not survive 
breast cancer. BRAF is marginally higher in patients who experience a recurrence, but this is not 
statistically significant. (B) BRAF expression levels separate patients into different DFS groups, 
albeit not statistically different (p = 0.074). Statistically different (C) DMFS and (D) DSS groups 
are observed in ER+ endocrine treated patients based on high expression levels of BRAF. 
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3.4 Discussion 
 The aim of this study was to identify molecular pathways that contribute to alcohol 
response in ER+ breast cancer cells. We first established that alcohol increased estrogen (E2)-
dependent cell proliferation but it did not promote proliferation in estrogen-starved cells (Figure 
3.1A), demonstrating that estrogen potentiated alcohol-induced cell proliferation. This contrasts 
with other studies, which were not able to identify the link between alcohol and estrogen in cell 
proliferation assays [203], due to the lack of experiments performed on cells grown in estrogen-
depleted medium containing growth factors.  Furthermore, we also identified the optimal 
concentration of alcohol for evaluating proliferative responses in breast cancer cells while 
maintaining physiologically attainable levels of alcohol. The most robust proliferative response 
was observed in MCF-7 cells treated to 43.4 mmol/L alcohol (Figure 3.1B). To address concerns 
of potential cytotoxic effects of alcohol, previously published studies determined that cytotoxicity 
occurs at very high levels of alcohol treatment (> 425 mmol/L), concentrations which were not 
evaluated in our study [194]. However, we found that the alcohol-dependent proliferative 
concentration window (between 21.7 mmol/L and ~65.1 mmol/L alcohol) was much lower than 
the cytotoxic dose of alcohol (>425 mmol/L alcohol). These studies clarified the optimal 
parameters for studying ethanol response, which was estrogen-dependent and fell well below 
cytotoxic thresholds observed in other studies.  
Estrogen signaling regulates and is highly integrated with growth factor signaling 
networks. We determined that alcohol promoted a known key regulator of estrogen-induced cell 
proliferation, the phosphorylation of ERK1/2, independent of estrogen (Figure 3.1C). 
Phosphorylated ERK1/2 are required for G1-S transition, and are thought to grant permissions for 
early events in G1 by up-regulating pyrimidine synthesis, regulating protein translation, or 
activating transcription factors involved in subsequent cell cycle processes [205-208]. It appears 
from these results that alcohol promoted both estrogen- and alcohol-specific responses, as 
increased pERK1/2 did not result in increased proliferation in the absence of estrogen. Potential 
mechanisms of ERK1/2 regulation have been proposed in other studies. Increased ERK signaling 
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could be due to the inactivation of phosphatases by reactive oxygen species (ROS) generated 
from alcohol detoxification, allowing for the accumulation of activating phosphorylation marks on 
growth factor receptors [209-211]. An alternative mechanism of the effects of alcohol on growth 
factor signaling pathways is that alcohol generated ROS lead to the inappropriate activation of 
matrix metalloproteinases, which are known to stimulate the activity of growth factor signaling 
ligands [193,211]. Regardless, these results form an important link between the two critical 
pathways in breast cancer, growth factor signaling and estrogen signaling, which are both 
regulated by alcohol.  
Alcohol has been shown to up-regulate the expression of an estrogen-responsive 
luciferase reporter gene [189], an effect which was shown to require estrogen. However, the 
effect of alcohol on the expression of ER target genes on endogenous promoters has not been 
extensively explored. We showed that alcohol further increased GREB1 expression after 
estrogen treatment, suggesting that alcohol promotes hyper-activation of estrogen signaling in 
breast cancer cells (Figure 3.1D). TFF1/pS2, however, did not respond to alcohol treatment, 
possibly due to ER saturation of that promoter, negative feedback loops on transcription of the 
gene target, treatment time conditions, or was otherwise insensitive to the effected mechanisms 
of alcohol treatment. These findings contrasted with another study that described a TFF1/pS2 
response to alcohol treatment, albeit the regulation was relatively subtle. We were unable to 
reproduce this effect in MCF-7 cells, possibly due to differences in experimental design [203].  
From genome-wide microarray studies of alcohol treated cells, we first observed that a 
significant proportion of the genome responded to alcohol treatment (Figure 3.2A). Due to the 
depletion of estrogen in the cell culture medium, we were able to assess whether alcohol could 
transactivate ER target genes independent of estrogen. Surprisingly, given the published reports 
of the effects of alcohol on ER, relatively few estrogen responsive targets were found to overlap 
with alcohol responsive genes, suggesting that alcohol is not an estrogen mimetic. These data 
also suggest, especially in light of the estrogen-independent effect of alcohol on ERK1/2 
phosphorylation, that alcohol-specific genes may potentially enhance estrogen dependent cell 
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proliferation. To test this hypothesis, alcohol responsive genes were further analyzed for 
statistically enriched gene ontology categories. Cell cycle genes (CCND2, RAD17, EP300) were 
up-regulated in MCF-7 cells treated with alcohol (Table 3.2).   
Genes involved in protein phosphorylation (ROCK1/2, JAK2, SMAD5) and 
dephosphorylation (DUSP1/12, BCL2, PTP) were also regulated by alcohol treatment. As 
previously mentioned, cell cycle machinery is heavily dependent upon posttranslational 
modifications for correct regulation of growth factor signaling cascades, which could explain the 
enrichment of gene ontology categories involved in general protein phosphorylation. Genes 
involved in oxidative-reduction responses (P53, SOD1, HMOX1) and apoptotic genes (CASP2, 
BID, VIM) were enriched in the down-regulated alcohol specific gene subset. These data indicate 
that alcohol regulates a number of pathways that have known critical roles in breast 
carcinogenesis.  
To ascertain the clinical significance of the alcohol-responsive genes, their expression 
profiles and association with disease outcomes were analyzed in a microarray dataset from 
tumors obtained from a cohort of patients who received endocrine therapy. Expression profiles of 
both up-regulated (Figure 3.2B) and down-regulated (Figure 3.2C) genes were strongly 
associated with metastasis (DMFS) and death (DSS). It is not clear from these data what roles 
these genes, as a whole, may play in breast carcinogenesis, disease progression, and response 
to SERMs, but their association with response to endocrine therapy suggests that alcohol 
treatment affects the expression of a large number of genes which, at the very least, are 
prognostic markers of therapeutic response and may function in key molecular pathways and 
mechanisms. At the molecular level, normal ER activity in breast cancer cells is antagonized by 
SERMs, which prevents estrogen-dependent cell proliferation [212,213]. Due to the differences in 
patient outcomes based on the gene expression profiles in patients of alcohol responsive genes, 
we suspected that alcohol might promote breast cancer cell proliferation even in the presence of 
tamoxifen. In agreement with this hypothesis, we determined that alcohol treatment attenuated 
tamoxifen suppression of cell proliferation in MCF-7 (Figure 3.3A) and T47D cell lines (Figure 
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3.3B). MDA-MB-231 cells did not respond to any of the treatment conditions, suggesting that ER 
and ER- associated factors mediate the effects of tamoxifen and alcohol. Several mechanisms of 
tamoxifen insensitivity have been previously identified. BRCA1 levels have been shown to be 
down-regulated by alcohol treatment [189]. Down-regulated BRCA1 levels lead to increased cell 
proliferation in the presence of tamoxifen by altering its interactions with transcriptional 
coregulators and alter the nature of ligand-bound ER and its downstream transcriptional 
responses [213]. Alternatively, amplified growth factor signaling can lead to increased cell 
proliferation in the presence of tamoxifen. In this study, we showed that growth factor signaling 
(pERK1/2) is activated in response to alcohol treatment, which has been shown in other studies 
to be up-regulated in tamoxifen resistant tumors (Figure 3.1C) [212]. These data together provide 
experimental evidence that alcohol can directly block the effects of tamoxifen and may lead to 
poor clinical outcomes and responses to therapy.  
To further determine the mechanisms of action of alcohol in breast cancer biology, 
individual responsive genes were analyzed for differential expression based on clinical outcomes 
and response to endocrine therapy in ER+ breast cancer patients (Table 3.4). WISP2, for 
instance, is consistently down-regulated in ethanol treated cells, and has been shown to prevent 
migration in MCF-7 cells by up-regulating E-cadherin expression and down-regulating MMP9 
activity [190]. The repressed gene dehydrogenase/reductase enzyme 2 (DHRS2) is expressed in 
MCF-7 cells, and is more highly expressed in luminal cells compared to basal cells, suggesting a 
link between higher expression of this protein and a less aggressive luminal phenotype [214]. 
H19, or maternally expressed H19, is a long non-coding RNA that has been shown to attenuate 
let-7 activity, a microRNA that regulates cell proliferation and apoptosis [215]. Deletions of the 
H19 mRNA have also been shown to lead to overgrowth in transgenic mouse models, possibly 
due to disrupted IGF-2 regulation [216]. Short-chain dehydrogenase/reductase 3 (DHRS3) has 
been identified as a p53 responsive gene, and functions to reduce all-trans-retinal to replenish 
bleached retinoids in the visual cycle [217]. DHRS3 is potently induced by retinoic acid, an 
antiproliferative vitamin-A derivative so alcohol may interact with vitamin-A associated pathways 
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in breast cancer cell lines [218].  Transforming growth factor β-induced (TGFBI) is a secreted 
protein and is also responsive to retinoic acid treatment in MCF-7 cells and has been shown to 
prevent both anchorage-independent growth in MCF-7 cells and the development of metastatic 
lesions in mouse xenograft models [42] [219]. The SCL/TAL1 (STIL) interrupting locus gene is 
required for cell-cycle progression, as well as for centriole biogenesis and function [220,221]. 
STIL attenuation prevents tumor growth in mouse colon cancer xenograft models [222]. The 
functional studies in this paper focused on BRAF, an effector of the growth factor signaling and 
upstream regulator of the mitogen-activated protein kinase/ERK cascade and a therapeutic target 
in other cancers such as melanoma [223,224]. The observed effects of up-regulated ERK1/2 
phosphorylation in response to alcohol treatment suggest a role for BRAF in alcohol responsive 
signaling pathways and effects (Figure 3.1C).  BRAF is a novel alcohol- and estrogen-responsive 
gene, and its transcript levels were negatively correlated with patient survival and response to 
endocrine therapy (Figure 3.5). These findings suggest that alcohol inappropriately promotes 
sustained expression of BRAF, even in the absence of estrogen, in women who consume alcohol 
and may thereby mimic or enhance the effects of estrogen in increasing breast cancer risks. 
These findings not only shed light on mechanistic actions of alcohol in breast cancer but also 
provide insights into the cross-talk between alcohol and known and novel oncogenic pathways in 
breast cancer in general 
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3.5 Conclusions and Future Directions 
Our interests in the effects of alcohol on estrogen signaling are based partially on 
previously published studies, which have shown that alcohol regulates estrogen receptor 
expression and transcriptional activity [189,203]. In this study, we investigated the effects of 
alcohol on estrogen and growth factor signaling. We were able to demonstrate enhanced cell 
proliferation and increased markers of growth factor signaling in breast cancer cells. Future 
experiments should attempt to identify causal links between alcohol treatment and growth factor 
signaling, which would allow for a more complete atlas of signaling with regards to alcohol in 
breast cancer.  We then identified gene networks regulated by alcohol that were involved in 
clinical outcomes in breast cancer patients, and determined the effects of alcohol on the response 
of ER+ cell lines to tamoxifen treatment. These characterizations are important, especially for 
breast cancer patients who are currently undergoing treatment for their breast cancer, or have 
had breast cancer and are in remission. We then characterized the effects of individual alcohol 
responsive genes on breast cancer cell biology. Future studies on these mechanisms will 
hopefully address several open questions with regards to alcohol response in breast cancer cells. 
First, a more complete analysis of the effects of alcohol on estrogen signaling is needed.  
To better understand the effects of alcohol on estrogen response, a four-part microarray 
is required that adds an estrogen treatment to alcohol treated cells (as the original microarray 
study presented here was carried out on estrogen starved cells treated with alcohol). This would 
allow us to test the hypothesis that alcohol amplifies estrogen dependent transactivation. Due to 
the increase transcription of these genes, chromatin immunoprecipitation experiments can be 
carried out on the alcohol associate EREs, allowing for the identification of increased ER binding 
or stability.  
Changes to metabolism of NR signaling compounds were suspected due to the 
repression of a subset of retinoic acid responsive genes in our microarray study. Very little is 
known about endogenous retinoids in breast cancer. However, Chen et al. carried out a study 
wherein radioactive retinol was incubated in the cell culture medium of breast cancer cell lines 
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[225]. The cells were then able to metabolize retinol into a variety of forms. Breast cancer cell 
lines do not follow the standard metabolic pathways observed in the eye and adipose tissue, 
which involves the conversion of retinol to retinoic acid. ER+ breast cancer cell lines convert 
retinol to 4-oxoretinol instead. Interestingly, 4-oxoretinol has been shown to suppress cell 
proliferation similar to retinoic acid treatment. With an endogenous RXR/RAR ligand in mind, we 
carried out HPLC experiments to determine whether alcohol altered intracellular retinoid levels. 
There was no difference in intracellular retinol levels due to alcohol treatment, but the HPLC 
instrument lacked the sensitivity to detect 4-oxoretinol in MCF-7 breast cancer cells. Detection of 
these compounds require incubation with radioactive retinol and subsequent analysis on the 
appropriate HPLC instrument.  
Lastly, studies of the effects of alcohol in mouse models are severely lacking. Animal 
studies are necessary because they measure disease parameters that are deficient in a cell 
culture, such as the effects of other cell types (stromal cells) and secreted factors that serve 
ultimately to model disease progression in human cancer patients.  Currently, only two studies 
have been carried out to determine the effect of alcohol on breast cancer progression in live 
animals. In both cases, lung metastasis was their experimental readout. One study showed a 
suppressive effect of alcohol on metastasis, which is in contradiction to the pro-carcinogenic role 
in our studies [195]. However, this study utilized an ER- cell line, which does not represent the 
standard pathological breast cancer subtype associated with alcohol consumption, as these as 
alcohol related cancers tend to be ER+/PR+. Another study used an ER+ cell line but carried out 
the experiment in male mice that lack estrogen, the driving force of proliferation in ER+ cell lines 
[196]. These results therefore do not address the effects of alcohol in a context that has been 
shown to potentiate its formation and development. Future studies on mouse models of breast 
cancer should also test the effects of alcohol on tamoxifen activity, which we have shown to be 
attenuated by alcohol treatment. These findings and future directions shed light on mechanistic 
actions of alcohol in breast cancer, and are suggestive of extensive cross-talk between several 
known oncogenic pathways in breast cancer.  
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